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CHAPTER 1 
 
INTRODUCTION 
 
 
 
 
1. 1. Cardiovascular diseases and heart failure 
Cardiovascular diseases (CVDs) are a group of heart and blood vessels disorders which 
includes coronary heart and cerebrovascular disease - or stroke - (diseases of the blood 
vessels supplying the heart muscle or the brain, respectively), peripheral artery disease 
(disease of the blood vessels supplying arms and legs), rheumatic heart disease (damage 
to the heart muscle and heart valves from rheumatic fever, caused by streptococcal 
bacteria), congenital heart disease (CHD, malformations of heart structure existing at 
birth), hypertension (high blood pressure), and heart failure (HF). As reported by the 
World Health Organization (WHO), CVDs are the leading causes of mortality in the 
World, occurring equally in men and women. They are no longer diseases of the 
developed Countries: to date, about 80% of all cardiovascular disease deaths worldwide 
take place in developing, low and middle-income Countries. It is has been estimated by 
the WHO that by 2015, CVDs will be the leading cause of death in developing 
Countries, interesting almost 20 million people.  
The most relevant causes of cardiovascular diseases are known as “modifiable risk 
factors” and include unhealthy diet, physical inactivity and tobacco use. The 
consequences of unhealthy diet and physical inactivity, called “intermediate risk 
factors”, are increases in blood lipid and glucose contents and obesity. 
The major biological risk factors for CVDs are high blood pressure, high blood 
cholesterol, overweight and obesity, and the chronic disease of type 2 diabetes. A 
condition of great importance, among cardiovascular diseases, is represented by heart 
failure. Common causes of HF include myocardial infarction and other forms of 
ischemic heart disease, hypertension, valvular heart disease and cardiomyopathies1. A 
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failing heart is characterised by a pathological structure or function which reduces its 
ability to supply the body with a sufficient blood flow. Heart failure can be categorised 
taking into account different aspects of the disease, for example: 
1) the myocardial portion interested (left heart failure or right heart failure); 
2) whether the abnormality is due to a myocardial contraction (systolic dysfunction) or 
relaxation (diastolic dysfunction); 
3) whether the problem is primarily an increased venous back pressure to the heart 
(backward failure), or a failure to supply adequate arterial perfusion from the heart 
(forward failure); 
4) the degree of functional impairment conferred by the failure. 
The main functional classification is the New York Heart Association (NYHA) 
Functional Classification2, which takes into account the following four classes of HF: 
Class I: no limitation is experienced in any activities; there are no symptoms from 
ordinary activities; 
Class II: slight, mild limitation of activity; the patient is comfortable at rest or with mild 
exertion; 
Class III: marked limitation of any activity; the patient is comfortable only at rest; 
Class IV: any physical activity brings on discomfort and symptoms occur at rest. 
This score documents severity of symptoms, and can be used to assess response to 
treatment. The American College of Cardiology (ACC)/American Heart Association 
(AHA) working group in 2005 introduced a new classification of HF3, based on four 
failure stages: 
Stage A: Patients at high risk for developing HF in the future but no functional or 
structural heart disorder; 
Stage B: a structural heart disorder but no symptoms at any stage; 
Stage C: previous or current symptoms of heart failure in the context of an underlying 
structural heart problem, but managed with medical treatment; 
Stage D: advanced disease requiring hospital-based support, a heart transplant or 
palliative care. 
The Stage A, which describes a pre-heart failure condition when treatments 
presumably prevent the progression to effective symptoms, lacks a corresponding 
NYHA class; ACC Stage B would correspond to NYHA Class I, ACC Stage C 
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corresponds to NYHA Class II and III and ACC Stage D overlaps with NYHA Class 
IV. 
In the present study we have pointed out attention on two of the principal causes 
leading to the onset of heart failure: the presence of cardiomyopathies and the ischemic 
damage due to post-ischemic reperfusion injury.  
 
1. 1. 1. Dilated cardiomyopathy 
Dilated cardiomyopathy (DCM), also known as congestive cardiomyopathy, is the most 
common form of cardiomyopathy and it is more frequent in men, occurring also in 
children. It is a condition in which the heart becomes weakened and enlarged, and can 
not pump blood efficiently. The decreased heart function can affect the lungs, the liver, 
and other body systems. In DCM a portion of myocardium is dilated and the left and/or 
right systolic pump function of the heart is impaired. This leads to a progressive 
hypertrophy and to the complex process known as cardiac remodelling, a whole of 
structural and functional alterations in the heart which arises also from chronic pressure 
overload, chronic volume overload or myocardial infarction (MI). 
It has been estimated that about one in tree cases of congestive heart failure (CHF) 
is due to dilated cardiomyopathies. The causes leading to the onset of DCM are 
different, for example it can be due to fibrous change of the myocardium from a 
previous myocardial infarction, or it can be the late phase of acute viral myocarditis, 
possibly mediated through an immunologic mechanism4. Moreover, alcohol abuse, 
pregnancy or thyroid disease may lead to a reversible form of DCM. Whenever the 
causes of DCM remain unknown, this cardiomyopathy is indicated as “idiopathic”. 
Frequently (in the 20-40% of cases) patients have a familiar form of DCM, showing 
mutations of gene encoding for cytoskeletal or contractile proteins5. In the case of gene 
mutations, the most common form of transmission of the disease is with an autosomal 
dominant pattern. The progression of heart failure is associated with left ventricular 
remodelling, which manifests as gradual increases in end-diastolic and end-systolic 
volumes, wall thinning, and a change in chamber geometry to a more spherical, less 
elongated shape. This process is usually associated with a continuous decline in ejection 
fraction. The concept of cardiac remodelling was initially developed to describe changes 
which occur in the days and months following myocardial infarction, but it has been 
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extended to cardiomyopathies of non-ischemic origin, such as idiopathic dilated 
cardiomyopathy or chronic myocarditis, suggesting common mechanisms for the 
progression of cardiac dysfunction.  
 
1. 1. 2. Maternally inherited mitochondrial cardiomyopathy 
Over the last years, mutations in human mitochondrial deoxyribonucleic acid (mtDNA) 
have become increasingly recognised as causes of diseases6,7. An increasing number of 
maternally inherited mtDNA point mutations have been described, affecting protein 
coding, ribosomal ribonucleic acid (mt-rRNA) or, more frequently, transfer ribonucleic 
acid (mt-tRNA) genes8. The majority of reported pathogenic mtDNA mutations are 
heteroplasmic, a situation in which both the mutated and the wild-type forms of mtDNA 
are present within the same cell. Homoplasmic mtDNA mutations (in which all copies 
of the genome are affected) have been reported in association with tissue-specific 
disease, such as Leber’s hereditary optic neuropathy (LHON) and sensorineural hearing 
loss, affecting protein-encoding9,10, 12S mt-rRNA11 and the mt-tRNASer(UCN)12 genes. A 
number of mtDNA point mutations have been described in patients with 
cardiomyopathy13,14. In a recent study of Taylor and colleagues15, two unrelated families 
with isolated maternally inherited cardiomyopathy (MIC) with a hypertrophic 
phenotype due to a homoplasmic point mutation (4300A>G) in the mitochondrial 
transfer ribonucleic acid isoleucine (mt-tRNAIle) gene were identified. In both families, 
the clinical features and associated histochemical and biochemical abnormalities were 
confined to the heart. Heart tissue from affected family members showed a severe defect 
in respiratory chain enzyme activity and low steady-state levels of the mature mt-
tRNAIle. Of note, comparably low levels of tRNAIle were present in skeletal muscle, 
which failed to show either a biochemical or a clinical defect. The illness had an early 
onset and an adverse clinical course in both families, with rapid progression of left 
ventricular hypertrophy to dilation and cardiac failure, necessitating heart transplant in 
two patients. 
Mutations in human mtDNA cause a large variety of multi-system disorders 
whose main unifying feature is the altered energy homeostasis (for example a reduced 
adenosine triphosphate [ATP] production). Highly energy-dependent tissues, such as the 
central nervous system and skeletal and cardiac muscle, are commonly involved7. 
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Cardiac dysfunction can occur as the sole or predominant symptom and often takes the 
form of hypertrophic cardiomyopathy14. The molecular events linking mtDNA defects 
to cardiac hypertrophy are unknown. Studies of experimental models suggest that both 
energy derangements and increase of mitochondrial-derived reactive oxygen species 
(ROS) could play a role in the development of cardiac dysfunction in MICs16,17. In 
addition, mitochondrial proliferation, a well recognized compensatory mechanism in 
mitochondrial disease, could contribute to cardiomyopathic remodelling through 
mechanical dysfunction18.  
 
1.1.3. Ischemic heart disease 
 Ischemic heart disease (IHD) is a pathological condition arising from a myocardial 
ischemia, due to a reduced blood supply to the heart muscle. Generally IHD is a 
consequence of coronary artery disease (CAD, imputable to coronary atherosclerosis). 
Like the others CVDs, it is principally due to smoke, hypercholesterolemia, diabetes 
and hypertension and its risk increase with age. IHD is more frequent in people who 
have close relatives with ischemic heart diseases. It is the most common cause of death 
in Western Countries, and a major cause of hospital admissions. 
 
1. 1. 4. Ischemia/reperfusion injury and cardiac myocytes homeostasis 
When the heart undergoes a pathophysiological stress, such as during the ischemic 
phase of acute myocardial infarction (AMI), a part of cardiac myocytes, the contractile 
cells of the heart, can die, leading to a reduction in cardiac activity. Though restoration 
of coronary blood flow to ischemic myocardium (reperfusion phase) clearly represents a 
prerequisite for myocardial salvage, reperfusion is also able to emphasize ischemic 
injury, leading to cardiac myocytes irreversible damage and consequent death. As 
cardiac myocytes are terminally differentiated cells that withdraw from the cell cycle in 
the perinatal period, the only way the survival myocytes have to redress this condition is 
to increase cellular size and myofibrillar content by a process known as hypertrophy. 
Ventricular hypertrophic growth is an adaptation occurring in response to heart 
dysfunction and it is realized by both a regulation of existing proteins (through 
phosphorylation or dephosphorylation) and a modification in gene expression with a 
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subsequent change in new proteins synthesis. In the short term such hypertrophy is 
beneficial and facilitates survival, but this "compensated" hypertrophy may degenerate, 
leading to heart failure with its associated morbidity and mortality. A common marker 
of cardiac myocytes hypertrophy is the increased expression of immediate early genes 
(IEGs), such as c-fos, c-jun and egr1, and of genes typically expressed in the early 
development (e.g. genes for myosin heavy chain, MHC, and atrial natriuretic factor, 
ANF, or B-type natriuretic peptide, BNP)19. Moreover, a modification in gene 
expression pattern is also observed during cardiac myocytes apoptosis.  
A range of stimuli promote hypertrophy including Gq protein-coupled receptor 
(GPCR) agonists (e.g. endothelin-1, ET-1; -adrenergic agonists), receptor protein 
tyrosine kinase (RPTK) ligands or mechanical stretch/strain20,21. Other 
pathophysiological stimuli promote apoptosis/necrosis, particularly those associated 
with increase oxidative stress (e. g. in the case of ischemia/reperfusion) but also, for 
example, death receptor ligands (e.g. Fas ligand) or pro-inflammatory cytokines (e.g. 
interleukin-1, IL1 ; tumor necrosis factor, TNF)22. However, the effects of specific 
stimuli are not always well defined and the response of a particular cardiac myocyte to 
any stimulus, whether apoptosis/necrosis or cell survival with/without hypertrophy, 
depends on the degree of stress and on the balance of cytoprotective Vs pro-death 
signals/proteins within the cell. Thus, high levels of oxidative stress promote cardiac 
myocyte necrosis, lower levels induce apoptosis and sub-toxic levels may be 
cytoprotective or even pro-hypertrophic23. Furthermore, healthy cardiac myocytes 
appear to be resistant to death-inducing signals (e.g. via the death receptor Fas) unless 
they have been previously compromised (e.g. by ischemia/reperfusion)24,25. Moreover, 
stimuli which promote cardiac myocyte hypertrophy (e.g. phenylephrine, an -adrenergic 
agonist19) or are associated with physiological growth (e.g. insulin26) are also 
cytoprotective27-29.  
The various hypertrophic, survival or death stimuli activate intracellular signalling 
pathways in cardiac myocytes, leading to changes in protein phosphorylation which 
elicit the phenotypic changes. For example, GqPCRs (signalling through protein kinase 
C, PKC) or RPTKs potently activate the extracellular signal-regulated kinases 1 and 2, 
members of the mitogen-activated protein kinases (MAPKs) family, which are 
particularly implicated in hypertrophy and/or cytoprotection19,30,31. Other MAPKs (e.g. 
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JNKs; p38-MAPKs, ERK5) are also implicated in cardiac hypertrophy, although JNKs 
and p38-MAPKs may regulate apoptosis and ERK5 is specifically implicated in the 
response to gp130 receptor ligands. The calcineurin/NFAT signalling pathway may be a 
specific hypertrophic signal responding to changes in intracellular Ca2+30,32. As in other 
cells, activation of phosphoinositide 3-kinase (PI3K) and protein kinase B (PKB) in 
cardiac myocytes (e.g. in response to insulin) is potently cytoprotective33. Notably, 
many of these same signalling pathways are activated by pro-apoptotic stresses. For 
example, oxidative stresses (including ischemia/reperfusion) or pro-inflammatory 
cytokines activate ERK1/2, JNKs, p38-MAPKs and PKB in cardiac myocytes and the 
heart34-37. Presumably, the precise phenotypic outcome depends on the relative 
activation and integration of these signals. 
Acute insults, such as an ischemic event, are associated with an inflammatory 
response and alterations in cardiac myocytes gene expression. This condition results in 
functional, structural and molecular changes that lead to ventricular remodelling38. 
During early inflammatory phase, a rapid induction of interleukin 6 (IL-6) gene has 
been reported39,40. IL-6 is required for the activation of the JAK-STAT pathway and its 
serum levels have been found increased in a pathological hypertrophic condition. In a 
very recent study, Sen and co-workers have explored the early and the late 
inflammatory phase of ischemic-reperfused rat hearts by DNA microarrays40. Through 
such an exhaustive technique, they have evaluated the pattern of some candidate genes 
implicated in the response against I/R and they have pointed out the necessity of global 
gene analysis regarding a complex disease such as myocardial infarction. Moreover, 
Sen and colleagues have documented a rapid induction of IL-18 gene in the early 
inflammatory phase of reperfusion40; IL-18 serum levels have been identified as strong 
predictors of cardiac mortality in patients affected by coronary artery disease41. An 
increase in endothelial type gp91phox gene (Cybb), the catalytic subunit of NADPH 
oxidase, has been also detected. This observation contributes to explain the well 
documented increase in ROS production during reperfusion. Caspases-2 (initiator), -3 
(effector) and -8 (initiator) are induced after myocardial infarction40,42; despite caspase-
8 is thought to be required for the growth and development of myocardial cells43, it has 
not yet been fully clarified if it plays also a role in post-infarction myocardial 
remodelling. Collagen type I and III is found to be increased after post-ischemic 
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reperfusion40,44. Collagen, the major extra-cellular matrix protein in the heart, is 
organized in a complex structure of fibres and represents a crucial target for anti-
remodelling and cardioprotective therapy. A great number of both basic research 
laboratories and clinicians in the World are focusing on the molecular mechanisms 
leading to heart failure but despite increasing studies on this field, there is still lack of 
effective protective strategies. 
 
 
1. 2. Oxidative stress: the balance between reactive oxygen species 
production and degradation  
The mechanisms responsible for the gradual development of CHF in response to MI, 
sustained pressure overload or other diseases are undoubtedly multifactorial and are the 
subject of intense investigation45 performed by many research groups. Over the past 20 
years, significant evidence has suggested a role for increased oxidative stress in the 
pathophysiology of CHF46. As a matter of fact, it is well established that patients with 
CHF show an enhance in oxidative stress (e.g., elevated plasma markers of oxidative 
stress), which correlates with myocardial dysfunction and the overall severity of heart 
failure47,48. Not only CHF but also its precursors are associated with evidence of 
increased oxidants production, which appears to contribute to disease pathophysiology. 
For example, the development of experimental pressure overload LVH or the transition 
of compensated LVH to failure in rodents are inhibited by antioxidants, supporting a 
role for reactive oxygen species production in cardiac hypertrophy in vivo49,50. 
Similarly, increased oxidants production is implicated in the development of adverse 
LV remodelling following experimental MI51,52 and in the onset of heart failure 
following ischemic and non ischemic cardiomyopathies53,54. 
Reactive oxygen species (ROS) are oxygen-based chemical species characterised 
by their high reactivity. They include free radicals (species with one or more unpaired 
electrons), such as superoxide (O2¯·) and hydroxyl (OH·), and non-radicals capable of 
generating free radicals, for example hydrogen peroxide (H2O2). The balance between 
ROS production and their removal by antioxidant enzymatic and non enzymatic systems 
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is responsible of the ‘‘redox state’’ of a cell; a pathological imbalance in favour of a 
ROS excess is termed oxidative stress. 
ROS are normally produced in the cell: a small amount of O2¯· derives as a 
byproduct from molecular oxygen during mitochondrial oxidative phosphorylation. A 
family of superoxide dismutase enzymes rapidly converts O2¯· to H2O2, which is itself 
broken down by glutathione peroxidase and catalase to H2O. However, under 
pathological conditions, the single-electron reduction of H2O2 may lead to the formation 
of highly reactive OH radicals. 
The pathophysiological effects of ROS depend on the type, the concentration and 
the specific site of production of oxidants. Moreover, the effects exerted in the 
cardiovascular system may be clustered into the following three types (Fig.1.1): 
1) When the local levels of ROS are high, they tend to react with numerous protein 
centres, DNA, cell membranes and other molecules, causing considerable cellular 
damage as well as generating other more reactive radicals.  
2) At lower concentrations, however, local targeted production of ROS serves as a 
second-messenger system that transmits biological information through the highly 
specific modulation of intracellular signalling molecules, enzymes and proteins. 
This action is known as “redox signalling” function and it is principally performed 
by H2O2, which is more stable and diffusible than superoxide, and by nitric oxide. 
Redox signalling pathways involve the activation of many signal transduction 
protein kinases and transcription factors, the stimulation of DNA synthesis and 
expression of growth-related genes55,56, and the regulation of myocardial excitation–
contraction coupling57.  
3) Finally, the superoxide radical can interact with nitric oxide leading to the formation 
of peroxynitrite (ONOO¯) and to the inactivation of nitric oxide and its biological 
role in vascular homeostasis and cardiac function modulation. The reaction is 
especially likely to occur when both O2¯· and nitric oxide levels are high and 
antioxidant activity is low. Interestingly, although high levels of ONOO¯ may 
induce non-specific toxic effects, at lower levels this species is itself capable of 
modulating signalling events in vivo, thus indicating an additional level of 
complexity. 
 
                                                                                                INTRODUCTION 
 18
 
 
Figure 1.1. The three principal consequences of oxidative stress increase. Effects are 
reported with regard to the cardiovascular system (modified figure from a review of 
Seddon M. and colleagues58). 
 
There are many potential sources of ROS in CHF, which have varying effects on 
pathophysiology. Excessive ROS derived from mitochondria have been shown in 
cardiomyocytes from experimental models of myocardial infarction and rapid pacing-
induced heart failure59. Xanthine oxidase also produces O2¯· as a byproduct of the 
terminal steps of purine catabolism and its expression and activity are increased in 
experimental models of CHF as well as in human end-stage CHF60. Nitric oxide 
synthase enzymes (NOS) normally produce nitric oxide, but they may instead generate 
O2¯· if they become ‘‘uncoupled’’, a state that is especially likely to occur in the setting 
of deficiency of the NOS cofactor BH4 or the NOS substrate L-arginine61. NOS 
uncoupling and subsequent O2¯· production are implicated in the genesis of vascular 
endothelial dysfunction in patients with heart failure62. Another important source of 
ROS and consequent oxidative stress are infiltrating inflammatory cells, especially in 
conditions such as myocarditis and in the early stages after myocardial infarction. 
Recent studies have suggested that multimeric enzymes called NADPH oxidases are 
especially important with regard to redox signalling in CHF and its antecedent 
conditions63,64. These enzymes catalyse electron transfer from NADPH to molecular 
oxygen, resulting in the formation of O2¯·. NADPH oxidase activity has been found 
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increased in experimental models of LVH and CHF as well as in end-stage failing 
human myocardium53,65-67 and in isolated cardiomyocytes subjected to 
ischemia/reperfusion injury68. Interestingly, ROS produced by NADPH oxidases can 
promote ROS generation by other sources, thereby amplifying their effect. For example, 
superoxide radical deriving from NADPH oxidase may oxidise and degrade BH4, 
thereby leading to NOS uncoupling, and this mechanism has been shown in diabetes 
and experimental hypertension61. Similarly, NADPH oxidase-derived ROS may also 
activate xanthine oxidase56. For more detailed elucidations about the NADPH oxidase 
enzyme structure and role in cardiac disease, see § 1. 3. 
In non pathological conditions, cells have a large variety of both enzymatic and 
non enzymatic antioxidant defences. Briefly, non enzymatic antioxidants are scavenger 
molecules which can react with radicals leading to less reactive products. Differently 
from antioxidant enzymes, which have specificity for particular radical compounds (for 
a more exhaustive description of antioxidant enzymes, see § 1. 4.), non enzymatic 
antioxidants show a wide range of activity. They may be clustered into water-soluble 
and liposoluble compounds69. Liposoluble antioxidants are vitamin E (α-tocopherol), 
vitamin A (retinol), β-carotene and ubichinol. Water-soluble antioxidants are vitamin C 
(ascorbic acid) and thiol compounds like cysteine and glutathione. Moreover, bilirubin 
and uric acid are important scavengers against radicals. Other important oxidants are 
proteins like transferrin, ceruloplasmin, and ferritin. 
Growing evidence implicates redox-sensitive pathways in the development of 
cardiac hypertrophy either in response to neurohumoral stimuli or chronic pressure 
overload. In cultured cardiomyocytes, hypertrophy induced by angiotensin II, 
endothelin 1, norepinephrine, tumour necrosis factor α or pulsatile mechanical stretch 
has been shown to involve intracellular ROS production and to be inhibited by 
antioxidants64. In vivo, the development of experimental pressure overload LVH in mice 
or guinea pigs is attenuated by antioxidants, thus implying a role for ROS. Recently, 
NADPH oxidases have been suggested to be key sources of these ROS. In experimental 
pressure overload LVH, an increase in NADPH oxidase activity and MAPK activation 
have been observed65. 
In vitro studies have shown that an increase in ROS production may be 
responsible of myocyte contractile function impairment, a central feature of CHF. 
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Contractile dysfunction has a multifactorial basis, involving changes in cardiomyocyte 
function as well as altered chamber structure and properties. Oxidative stress can act in 
this context through several mechanisms, including disruption of calcium cycling, 
altered myofilament responsiveness to calcium, and deleterious effects on cellular 
metabolism and energetics57,59,64. In some cases, xanthine oxidase60 and NADPH 
oxidase70,71 have been suggested to play an important role in this field. 
Excessive interstitial fibrosis is another important detrimental aspect of chronic 
LVH and CHF. Oxidative stress is well known to be profibrotic in many organs and this 
seems to be also true in the heart, where NADPH oxidase-derived ROS play a central 
role in this process70,72. Multiple underlying mechanisms are likely to be involved in the 
NOX2-dependent pro-fibrotic effects, including increased expression of pro-fibrotic 
growth factors and genes, increased activation of NF-kB, activation of matrix 
metalloproteinases, and inflammatory cell infiltration. 
Finally, growing evidence suggests an important role for increased oxidative stress 
in adverse left ventricular remodelling after myocardial infarction46. An increase in 
oxidative stress after myocardial infarction is well recognised, and in experimental 
models various antioxidant approaches (e.g., probucol, dimethylthiourea or genetic 
manipulation) have been shown to ameliorate the adverse remodelling. A significant 
factor for the detrimental effect of ROS in this setting is the activation of matrix 
metalloproteinases, which drive matrix turnover and promote left ventricle dilatation. 
The increase in ROS may be driven by stimuli such as activation of the renin 
angiotensin system, cytokine activation, local inflammation and mechanical stimuli. 
The main enzymatic complexes responsible for ROS generation in this context are 
NADPH oxidase73 and xanthine oxidase74.  
 
 
1. 3. The NADPH oxidase of cardiovascular system  
 
1. 3. 1. Generalities and history 
Reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is an enzyme 
which catalyses the production of superoxide radical (O2¯·) from oxygen, using 
NADPH or NADH - that is why the expression “NAD(P)H” is frequently used - as 
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electron donor. The enzyme was first identified in professional phagocytes 
(neutrophils75, eosinophils, monocytes and macrophages76) where it is involved in non-
specific host defence against microbes. In the phagocytes the oxidase is normally 
quiescent but becomes activated during phagocytosis, when it generates high levels of 
ROS and protons that are involved in the microbicidal process. Among the oxidising 
agents derived from NADPH oxidase, H2O2 is also included as a product of superoxide 
dismutation77. Unlike other sources of ROS, the NADPH oxidases clearly appear to 
have ROS generation as their primary function.  
Historically, a respiratory burst by cells was supposed to exist since the first half 
of the 20th century, even if the NADPH oxidase was not yet identified. These 
observations were done in sea urchin eggs, in phagocytes (in 1933)78, and in 
spermatocytes (in 1943)79. In 1961, Quastel and collaborators80 showed that the 
phagocyte respiratory burst led to the generation of hydrogen peroxide. There was a 
major controversy with regard to the main substrate for the enzyme system, as it could 
be NADPH or NADH. In 1964, Rossi and Zatti81 correctly proposed that a NADPH 
oxidase was responsible for the respiratory burst. Finally, in 1973 and in 1975 
respectively, Babior and co-workers reported that the initial product of the respiratory 
burst oxidase was superoxide and not hydrogen peroxide82 and that the enzyme was 
selective for NADPH over NADH by a factor of 10083. 
An important line of study that led to the discovery of the phagocyte NADPH 
oxidase came in 1957, from a clinical study of Berendes and colleagues84 who 
recognized a new and relatively rare syndrome in young boys who suffered from 
recurrent pyogenic infections that were accompanied with granulomatous reaction, 
lymphadenopathy, and hypergammaglobulinemia. The genetic disorder is now known 
as Chronic Granulomatous Disease (CGD). The significance of NADPH oxidase system 
is now well exemplified by this pathology. CGD causes recurrent and life-threatening 
infection since the phagocytes are deficient in the superoxide producing activity85,86. 
The lack in superoxide producing activity is due to the deficiency of one of the four 
phox (phagocytic oxidase) subunits, the components of NADPH oxidase. The disease is 
characterized by infections which begin very early in life and are frequently fatal87, 
although their severity tends to decrease when the patient is over twenty.  
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In 1978 Segal, Jones, and colleagues88,89 identified the cytochrome b558, which 
was missing in the leukocytes of many CGD patients. In the late 1980s, the gene coding 
for the catalytic subunit of the phagocyte NADPH oxidase, commonly referred to as 
gp91phox, was cloned by two distinct groups: Royer-Pokora and colleagues90 and Teahan 
and colleagues91. In the last decade, several homologues of this enzyme have been 
discovered in numerous other cell types, where they are involved in many different non-
phagocytic functions63,92. The discovery that non-phagocytic cells also contain 
superoxide-producing enzymes similar to the phagocyte NADPH oxidase has been 
accompanied by the observation that several gp91phox homologues are expressed in a 
variety of tissues. In 1999, on the basis of a BLAST (basic local alignment search tool) 
search using the protein sequence of gp91phox as a query, Prof. Lambeth and co-workers 
cloned the cDNA encoding a homologue of gp91phox, initially designated as MOX1 but 
presently termed NOX1 (NADPH oxidase), which is abundantly expressed in the 
colon93. Afterwards, using a similar strategy, additional homologues were identified by 
several other groups94-99. In particular, a phagocytic-like NADPH oxidase, NOX2 (also 
known as gp91phox, the core of the classical phagocyte NADPH oxidase) have been 
found in the cardiovascular system, were it markedly contributes to the ROS production 
process. NOX2 is expressed in several cell types, like endothelial cells100-103, 
cardiomyocytes72,104, and fibroblasts105. The other main isoforms that appear to be 
important in the cardiovascular system are NOX1, which is expressed in vascular 
smooth muscle cells (VSMC)106, and NOX4 which is expressed in endothelial cells107, 
cardiomyocytes108,109, VSMC110, and fibroblasts111. 
 
1. 3. 2. Membrane subunits 
The structure of the phagocytic NADPH oxidase is quite complex, as this is a 
multimeric enzymes with two membrane subunits, gp91phox (or NOX2) and p22phox, 
three cytosolic components, p67phox, p47phox and p40phox, and a low-molecular-weight G 
protein, either Rac1 or Rac2. The catalytic core of the phagocytic oxidase is the 
cytochrome b558, which comprises the two membrane subunits. gp91phox is considered to 
be directly involved in the superoxide production, since it contains binding sites for 
NADPH, flavine adenine dinucleotide (FAD) and two hemes, which constitute the 
complete electron-transferring apparatus from NADPH to molecular oxygen. The two 
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hemes have very low redox potentials and are both hexacoordinate. There are currently 
five human members identified in the NOX family (NOX1-5), where the founder 
member gp91phox has been renamed NOX2. Additionally, in humans, two thyroid 
NADPH oxidases, probably involved in thyroid hormone synthesis, were identified112-
114. Since the two enzymes contain not only a NADPH oxidase-homology region at the 
C-terminus but also a peroxidase domain at the N-teminal extracellular region, they 
have been designated as dual oxidases 1 and 2 (DUOX1 and DUOX2, respectively). 
 
 
 
Figure 1.2. The NOX domain (figure from Kawahara T. et al.115). 
 
The structure of gp91phox/NOX2 has been extensively studied. This protein has 
four conserved histidines, which ligate two hemes between the 3rd and 5th of six 
transmembrane (TM) α-helices, and six subregions that fold to provide binding cavities 
for FAD and NADPH. These canonical regions occupy about 35% of the 
gp91phox/NOX2 sequence and are grouped together under the definition of NOX 
domain. However, little is known about essential roles for the other regions. As shown 
in fig.1.2, all the members of the NOX family expressed a NOX domain containing, 
from the N-terminal to the C-terminal NOX region, a cluster of six transmembrane α-
helices (I through VI, represented with boxes in the figure), two hemes (represented 
with rhombi in the figure), and six predicted sub-regions that provide binding cavities 
for a co-enzyme FAD (FAD1 and FAD2) and for the substrate NAD(P)H (N-I, N-II, N-
III, and N-IV). In addition, NOX5 and Duoxes present an EF hand-containing calcium-
binding domain. Duoxes also show the peroxidase homology domain, as described 
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above (fig. 1.3). The NOX proteins are expressed in most eukaryotes including 
vertebrates, urochordates, echinodermates, nematodes, insects, fungi, plants amoeba, 
and red alga, but not in prokaryotes (from a study of Prof. Lambeth and co-workers115). 
 
 
 
Figure 1.3. Homology between some NOX/DUOX isoforms (figure from Kawahara T. 
et al.115). 
 
The catalytic subunit gp91phox/ NOX2 alone is inactive and must associate with 
p22phox, whose tail is in the cytosol, to form a non-covalent heterodimer known as 
flavocytochrome b558. The association between the p22phox subunit and the NOX subunit 
seems to be important for the stability of the complex as well as for the interactions with 
other protein-binding partners to assemble the active oxidase. 
All NOX/DUOX family members are transmembrane proteins that transport 
electrons across biological membranes to reduce oxygen to superoxide. The molecular 
mechanism at the basis of NOX-dependent superoxide production is quite different 
among all components of the NOX/DUOX family. In particular, tacking into account 
only mammalian NOX members, there are conserved structural properties of NOX 
enzymes that are common to all family members (the NADPH-binding site at the C-
terminus, the FAD-binding region, six conserved transmembrane domains and four 
highly conserved heme-binding histidines, two in the third and two in the fifth 
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transmembrane domain. Given the additional NH2-terminal transmembrane domain, the 
histidines are in the fourth and sixth transmembrane domains in DUOX proteins) and 
most data suggest that all NOX family members must be selective for NADPH over 
NADH. The following part is a brief description of NOX1-5 and of DUOX1-2. 
 
NOX1 
NOX1 was the first homolog of gp91phox/NOX2 to be described93,116. NOX1 and NOX2 
genes appear to be the result of a relatively recent gene duplication, as the number and 
the length of the exons is virtually identical between the two genes116. Similarly, at the 
protein level, there is a high degree of sequence identity (of about 60%) between NOX1 
and NOX293,117,118. The human and mouse NOX1 genes are located on the X 
chromosome. Most studies suggest a molecular mass of NOX1 in the range of 55–60 
kDa119-121. If these values are correct, NOX1 is most likely not N-glycosylated, despite 
the presence of two NXT/S consensus glycosylation sites in the extracellular domains. 
NOX1 is most highly expressed in colon epithelium116; however, it is also expressed in 
a variety of other cell types, including VSMC106, endothelial cells122, uterus93, 
placenta120, prostate93, osteoclasts123, retinal pericytes124, as well as in several cell lines, 
such as the colon tumor cell lines Caco-2, DLD-1 and HT-29 and the pulmonary 
epithelial cell line A549 (for a review see Bedard K. and Krause K. H.125). In addition to 
its constitutive expression in a variety of tissues, the NOX1 mRNA is induced under 
many circumstances. In vascular smooth muscle, platelet-derived growth factor 
(PDGF), prostaglandin F2α, and angiotensin II induce NOX1 expression106. Data on the 
subcellular localization of NOX1 are scarce, mainly because the generation of high 
quality antibodies against NOX1 (as well as for other NOX isoforms) turned out to be a 
challenge and some of the antibodies used were not subjected to rigorous validation 
protocols. Despite this limitation, several studies report a subcellular localization of 
NOX1; in keratinocytes, there were a weak cytoplasmic and a strong nuclear staining126. 
One study in vascular smooth muscle suggests an endoplasmic reticulum (ER) pattern, 
while another describes punctuate patches along cell surface membranes, possibly 
corresponding to a caveolar localization. In studies using a cell-free system, NOX1 is 
selective for NADPH over NADH as a substrate (for a review see Bedard K. and Krause 
K. H.125). The cytosolic subunits required for NOX1 activation are named 
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p41nox/NOXO1 (NOX organizer 1, a p47phox homolog) and p51nox/NOXA1 (NOX 
activator 1, a p67phox homolog)116,127. The proteins NOXO1 and NOXA1 exhibit almost 
the same domain arrangement as the classical p47phox and p67phox (fig. 1.4), and can 
interact with the target proteins thus-far identified for p47phox or p67phox, except that 
NOXA1 fails to bind to p40phox. 
 
 
 
Figure 1.4. Differences and homologies between p47phox/p67phox and NOXO1/NOXA1 
subunits (figure from Takeya R. and Sumimoto H.128). 
 
NOXO1 interacts via its SH3 domains with p22phox, as p47phox does. In addition, 
NOXA1 binds, via the N-terminal domain composed of four tetratrico-peptide repeat 
(TPR) motif, to Rac in a GTP-bound state (fig. 1.5). 
Although both novel and classical homologues are capable of activating NOX1 
and gp91phox/NOX2, NOXO1 and NOXA1 appear to prefer NOX1; p47phox and p67phox, 
on the other hand, likely activate gp91phox/NOX2 more efficiently. Consistent with the 
preference, colon epithelial cells, abundant in NOX1, exclusively express NOXO1 and 
NOXA1, whereas phagocytes that express large amounts of gp91phox/NOX2 contains 
solely p47phox and p67phox116,127. Differently from what happens in the phagocyte 
NADPH oxidase, where p47phox and p67phox are able to activate gp91phox/NOX2 only 
after specific stimuli, NOXO1 and NOXA1 are capable of activating NOX1 and 
gp91phox/NOX2 without cell stimulation under certain conditions. 
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Figure 1.5. Interactions between either p47phox/p67phox or NOXO1/NOXA1 and the 
other cytosolic subunits (figure from Takeya R. and Sumimoto H.128). 
 
Endogenous NOX1 in the colon epithelial adenocarcinoma Caco2 cells 
spontaneously generate superoxide, when NOXO1 and NOXA1 are co-expressed129 and 
both NOX1 and gp91phox/NOX2 are constitutively active in COS-7 or HEK293 cells, 
which ectopically express a pair of NOXO1 and NOXA1 or a pair of NOXO1 and 
p67phox116,127. On the other hand, when p47phox is expressed instead of NOXO1 in these 
cells, a stimulus such as phorbol 12-myristate 13-acetate (PMA) is absolutely required 
for activation of the oxidases. Thus, stimulus-independent activation of NOX1 and 
gp91phox/NOX2 seems to require NOXO1. In this context, it should be noted that 
NOXO1does not present a sequence homologous to the AIR region that prevents the 
SH3 domains of p47phox from interacting with p22phox (for details on the AIR region see 
§ 1. 3. 3.). Indeed the SH3 domains of NOXO1 are considered to be always in an 
accessible state to its target p22phox, hence the full-length of NOXO1 can bind to 
p22phox127, while the full-length of p47phox, in a resting state, can not.  
In addition the regulation mechanism of NOX oxidases by NOXA1 is not the 
same as that by its homologue p67phox. For instance, NOXA1 can not interact with 
p40phox, a dispensable but significant regulator of the phagocyte oxidase130. Hence the 
regulation mediated via p40phox is not expected in an activation system that uses 
                                                                                                INTRODUCTION 
 28
NOXA1. The N-terminal SH3 domain of p67phox is the most conserved module in this 
protein131, albeit its target protein remains unidentified. The absence of this SH3 domain 
in NOXA1 may suggest a difference between the homologues in oxidase activation. 
Moreover, in transfected cells, NOX1 is also able to use the p47phox and p67phox 
subunits, suggesting that cytosolic subunits are not specific for a given NOX protein116. 
In addition to its dependence on cytosolic subunits, NOX1 requires the membrane 
subunit p22phox119, even if this dependence is less forced than that observed for 
gp91phox/NOX2 and NOX3132. There is now also evidence for an involvement of the 
small GTPase Rac in the regulation of NOX1 activity132. Rac binds to the TPR domain 
of the activator subunit NOXA1133, but in analogy with gp91phox/NOX2, Rac activation 
of NOX1 might be a two step process that also includes a direct binding to NOX1.  
 
NOX2 
Most of what is known about the structure of the NOX isoforms is derived from studies 
on NOX2. Antibody mapping studies demonstrate a cytoplasmic localization of the C-
terminus134. Sequencing data and antibody mapping confirm a cytoplasmic N-
terminus91; taken together, the available data suggest that NOX2 has six transmembrane 
domains and that its COOH-terminus and its NH2-terminus are facing the cytoplasm. 
Human NOX2 is a highly glycosylated protein (the carbohydrate chains are composed 
of N-acetylglucosamine and galactose and, to a lesser extent, frucose, mannose, and 
glucose135) that appears as a broad smear on SDS-PAGE reflecting the heterogeneity of 
glycosylation. The fully glycosylated form runs with an apparent molecular mass of 70–
90 kDa. Removal of the carbohydrates by endoglycosidase F leaves a protein that runs 
at 55 kDa, demonstrating the extent of glycosylation135. NOX2 constitutively associates 
with p22phox, a subunit which stabilises NOX2 as demonstrated by the observation that 
phagocytes from p22phox-deficient patients have no detectable NOX2 protein (for a 
review see Bedard K. and Krause K. H.125). Activation of NOX2 requires translocation 
of cytosolic factors to the NOX2/p22phox complex. Once assembled, the complex is 
active and generates superoxide by transferring an electron from NADPH in the cytosol 
to oxygen on the luminal or extracellular space. NOX2 can be regarded as a 
transmembrane redox chain that connects the electron donor, NADPH on the cytosolic 
side of the membrane with the electron acceptor, oxygen on the outer side of the 
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membrane. It transfers electrons through a series of steps involving a FAD and two 
assymetrical hemes, with the inner heme binding to histidines H101 and H209 and the 
outer heme binding to histidine H115 and H222136. In the first step, electrons are 
transferred from NADPH to FAD, a process that is regulated by the activation domain 
of p67phox. NOX2 is selective for NADPH over NADH as a substrate, with Km values of 
40–45 µM versus 2.5 mM, respectively137. In the second step, a single electron is 
transferred from the reduced flavin FADH2 to the iron center of the inner heme. Since 
the iron of the heme can only accept one electron, the inner heme must donate its 
electron to the outer heme before the second electron can be accepted from the now 
partially reduced flavin, FADH. The force for the transfer of the second electron, while 
smaller (31 vs. 79 mV), is still energetically favourable. However, the transfer of the 
electron from the inner to the outer heme is actually against the electromotive force 
between these two groups. To create an energetically favourable state, oxygen must be 
bound to the outer heme to accept the electron138. When tissue distribution of total 
mRNA from various organs is investigated, NOX2 appears to be the most widely 
distributed among the NOX isoforms. It has been described in a large number of tissues, 
including thymus, small intestine, colon, spleen, pancreas, ovary, placenta, prostate, and 
testis (for a review see Bedard K. and Krause K. H.125). The message and the protein 
level for expression of NOX2 have been found in neurons, cardiomyocytes, skeletal 
muscle myocytes, hepatocytes, endothelial cells, and hematopoietic stem cells (for a 
review see Bedard K. and Krause K. H.125). In phagocytes, NOX2 localizes to both 
intracellular and plasma membranes in close association with the membrane protein 
p22phox139. In resting neutrophils, most of the NOX2 localizes to intracellular 
compartments, in particular secondary (i.e., specific) granules139 and tertiary (i.e., 
gelatinase-containing) granules140. Upon phagocyte stimulation, there is a translocation 
of NOX2 to the surface as the granules fuse with the phagosomal or the plasma 
membrane139. This fusion is thought to be a key event for the microbicidal activity of 
NOX2. In cells other than phagocytes, the subcellular distribution varies depending on 
the specific cell type. For example, in smooth muscle cells, NOX2 is found to co-
localize with the perinuclear cytoskeleton141.  
The human and mouse NOX2 gene is located on the X chromosome. NOX2 gene 
expression is inducible. This has been demonstrated in phagocytes in response to 
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interferon-γ (mRNA), in myofibroblasts after carotid artery injury (mRNA), and in 
cardiomyocytes after acute myocardial infarction (protein) (for a review see Bedard K. 
and Krause K. H.125). NOX2 expression is also increased in response to angiotensin II in 
adipose tissue (mRNA), aorta (mRNA), heart (mRNA), resistance artery vascular 
smooth muscle cells (mRNA and protein), and pancreatic islets (protein) (for a review 
see Bedard K. and Krause K. H.125). An increase in NOX2 levels is not invariably due 
to transcriptional activation. In the case of resistance arteries, the angiotensin II-induced 
NOX2 elevation may be due to increased de novo protein synthesis, regulated at a post-
transcriptional level142.  
 
NOX3 
NOX3 was described in the very last years143. NOX3 shares of about 56% amino acid 
identity with NOX2. The gene for human NOX3 is located on chromosome 6. NOX3 is 
a p22phox-dependent enzyme; its expression stabilises the p22phox protein144 and leads to 
p22phox translocation to the plasma membrane133. In functional studies, p22phox is 
required for NOX3 activation144, and truncated p22phox inhibits ROS generation by 
NOX3145. In the absence of cytosolic subunits, heterologously expressed NOX3 was 
found to be inactive146, weakly active143, or substantially active144. An enhanced 
activation of NOX3 in the presence of NOXO1 was found in all studies143. In vivo 
studies have demonstrated that inactivation of NOXO1 mimics the phenotype of NOX3-
deficient mice147. The results on the requirement for NOXA1 are contradictory: while 
some studies found enhancement of NOX3 activity through NOXA1143, others did 
not144. Thus the results of heterologous expression studies depend on the experimental 
conditions, and in vivo data with NOXA1-deficient animals will be necessary to clarify 
the issue. In heterologous expression studies, p47phox and p67phox are capable of 
activating NOX3143. The Rac dependence of NOX3 is also still unclear. Two studies 
suggest a Rac independence144, while the results of a third study suggest an effect133. 
The differences in the findings may be due to a less strict requirement for Rac in NOX3 
activation, or to the presence of endogenous Rac in the cells in which Rac independence 
was found. Biochemical evidence suggest a constitutive activation of the NOX3 
superoxide-generating system, infact NOXO1, the key subunit for NOX3 activation, 
constitutively activates NOX3 in reconstituted systems. However, the reason of such a 
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constitutively active ROS-generating system is much less clear from a physiological 
point of view and in vivo studies will be necessary to clarify the point. 
 
NOX4 
NOX4 was originally identified as a NADPH oxidase homolog highly expressed in the 
kidney98. NOX4 shares only about the 39% identity to NOX2. The gene for human 
NOX4 is located on chromosome 11. NOX4 antibodies recognise two bands, one of 75–
80 kDa and a second of 65 kDa from both endogenous NOX4-expressing cells (smooth 
muscle and endothelium) and NOX4-transfected Cos7 cells98. The subcellular 
distribution of the two bands is distinct148. The fact that two molecular masses are 
detected and that NOX4 contains four putative N-glycosylation sites might suggest that 
NOX4 is glycosylated, although treatment with N-glycosidase F failed to reduce the 
protein to a single band98. In addition to its strong expression in the kidney, NOX4 
mRNA is also found in osteoclasts, endothelial cells, smooth muscle cells, 
hematopoietic stem cells, fibroblasts, keratinocytes, melanoma cells, and neurons (for a 
review see bedard K. and Krause K. H.125). Moreover, Nox4 protein appears to be the 
most widely expressed isoform, being found in endothelial cells107, cardiomyocytes149 
and fibroblasts150,151. 
Induction of NOX4 mRNA expression is observed in response to endoplasmic 
reticulum stress, shear stress, carotid artery injury, hypoxia and ischemia, and 
transforming growth factor (TGF)-β1 and TNF-α stimulation of smooth muscle (for a 
review see bedard K. and Krause K. H.125). Up-regulation of NOX4 (mRNA and 
protein) has been reported in response to angiotensin II152. The angiotensin II-induced 
up regulation of NOX4 mRNA was prevented by pigment epithelium-derived factor 
(PEDF)152. Down regulation of NOX4 mRNA and protein is observed in response to 
PPAR-γ ligands153. In vascular smooth muscle, NOX4 is described in proximity to focal 
adhesions148, while in transfected cells, NOX4 localization is mostly observed in the 
ER. While a functional role for NOX4 in the ER is entirely possible, this localization 
may also represent an accumulation at its site of synthesis. In vascular smooth muscle 
and endothelial cells NOX4 expression in the nucleus is suggested by several lines of 
arguments (immunofluorescence, electron microscopy, nuclear Western blots, and 
nuclear ROS generation)148. It is however difficult to understand how a protein that 
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spans the membrane six times can be found in a presumably membrane-free space, such 
as the interior of the nucleus. NOX4 need p22phox for its ROS generation process154 (it 
co-localizes and co-immunoprecipitates with p22phox) and it is also able to stabilises the 
p22phox subunit119. p22phox mutants lacking the PRR in the C-terminus are still fully 
active in supporting NOX4 activity, while such mutants are not sufficient for NOX1, -2, 
and -3 activation. 
Moreover, NOX4 does not require cytosolic subunits for its activity, and upon 
heterologous expression, it is active without cell stimulation154. Yet, at least in some 
endogenously NOX4-expressing cells, a Rac requirement has been documented155. 
Whether the Rac requirement reflects a direct Rac/NOX4 interaction or is rather indirect 
remains to be established. NOX4 might be a constitutively active enzyme, but not all 
available data agree with this hypothesis. The mechanisms responsible for regulating 
the NOX4 activity remain poorly understood, but it is thought that the enzyme may be 
constitutively active and that increased activity may be related to an increased protein 
expression. NOX4 activation is observed in lipopolysaccharide (LPS)-stimulated 
HEK293 cells156, in insulin-stimulated adipocytes (569), in angiotensin II- or high 
glucose-stimulated mesangial cells155, and in PMA-stimulated vascular endothelial cells 
(494). Mechanisms of NOX4 activation might include a direct binding of TLR4 to 
NOX4156. 
 
NOX5 
NOX5 was discovered in 2001 by Cheng and colleagues95 and Banfi and co-workers94, 
separately. The human NOX5 gene is located on chromosome 15. Differently from the 
other NOX1–4 enzymes, the NOX5 isoforms described by Banfi (NOX5α, -β, -γ, and -
δ) showed a long intracellular N-terminus containing two cassettes of EF-hand calcium-
binding motif94,157. The NOX4 described by Cheng (NOX5ε or NOX5-S) lacks the EF-
hand region and therefore has an overall structure more similar to NOX1-495. NOX5 
protein gives a band of about 85-kDa on SDS-PAGE. This would be consistent with its 
predicted molecular mass and suggests that the protein is not glycosylated. As seen for 
NOX2, NADH cannot replace NADPH as a cytoplasmic electron donor for NOX5157. 
NOX5 mRNA expression is described in testis, spleen, lymph nodes, vascular smooth 
muscle, bone marrow, pancreas, placenta, ovary, uterus, stomach, and in various fetal 
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tissues94,95. Interestingly, NOX5 mRNA could not be detected within circulating 
lymphocytes94. No data on the tissue distribution or subcellular distribution of the 
NOX5 protein are available.  
Nothing is known about the activation of the EF hand deficient NOX5 ε; thus the 
activation mechanisms are based on studies using EF hand-containing NOX5 isoforms. 
NOX5 does not require p22phox for activity, as demonstrated by siRNA suppression of 
p22phox leading to a decrease in the activity of NOX1 to NOX4, but not of NOX5145, and 
it does not require cytosolic organizer or activator subunits94. As predicted by the 
presence of EF hands, activation of NOX5 is mediated by an increase in the cytoplasmic 
Ca2+ concentration157. The Ca2+-binding domain of NOX5 behaves as an independent 
folding unit and undergoes conformational changes in response to Ca2+ increase157. This 
is thought to activate the enzyme through an intramolecular protein-protein interaction 
between the Ca2+-binding region and the catalytic C- terminus of the enzyme94,157. 
Finally, the binding of Ca2+ to the N-terminal region may induce a conformational 
change of Nox5, which allows electron transport from NADPH to molecular oxygen. 
 
DUOX1 and DUOX2 
For several novel NOX isoforms, the identification of the protein preceded the 
definition of its function. In the case of DUOX1 and DUOX2, the situation was 
reversed. It had been known for a long time that thyroid epithelial cells produce H2O2 at 
the apical plasma membrane in a Ca2+- and NADPH-dependent manner158. Researchers 
in the thyroid field were actively looking for an NADPH oxidase. It took 15 years from 
the discovery of this function to the identification of DUOX proteins (originally called 
thyroid oxidase), which were identified from thyroid gland by two groups112,113. The 
genes for both human DUOX isoforms are located on chromosome 15. In addition to a 
NOX homology domain and two EF-hand regions, DUOX proteins have a seventh 
transmembrane domain at the N-terminus with an ectofacing peroxidase like domain. 
Within the NOX backbone, DUOX isoforms share about 50% identity with NOX2112. 
DUOX enzymes are glycosylated. Both DUOX1 and DUOX2 have two N-glycosylation 
states: the high mannose glycosylated form found in the ER, which runs by gel 
electrophoresis at 180 kDa, and a fully glycosylated form found at the plasma 
membrane that runs at 190 kDa159,160. Carbohydrate content analysis of plasma 
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membrane DUOX revealed specific oligosaccharides indicative of a Golgi apparatus 
processing. When totally deglycosylated, the molecular mass of both DUOX1 and 
DUOX2 drops to 160 kDa159. It is not clear whether the peroxidase homology domain 
of DUOX enzymes functions as a peroxidase. One study suggests that DUOX 
peroxidase homology domains, when expressed as recombinant proteins, have a 
peroxidase function114. However, the DUOX peroxidase homology domains lack many 
amino acid residues identified as essential for peroxidase function (for a review see 
Bedard K. and Krause K. H.125). The fact that a peroxidase is usually co-expressed in 
DUOX expressing systems, e.g., thyroid peroxidase in the thyroid gland and 
lactoperoxidase in salivary glands, also questions the peroxidase function of DUOX. 
This is particularly well documented for the thyroid, where thyroid peroxidase 
deficiency leads to severe hypothyroidism, due to a lack of peroxidase-dependent 
hormone synthesis161. Still, the peroxidase homology region of DUOX2 seems to be of 
functional importance, as hypothyroidism in patients with mutations in the extracellular 
domain has been reported162. Based on its homology with NOX2 and the fact that heme 
enzymes are monoelectron transporters, DUOX enzymes should generate superoxide. 
The substrate selectivity for human DUOX has not been defined; however, the 
GXGXXPF sequence typical of NADPH over NADH substrate selectivity is conserved. 
Both DUOX1 and DUOX2 are highly expressed in the thyroid112,113. In addition, 
DUOX1 has been described in airway epithelia and in the prostate (for a review, see 
Bedard K. and Krause K. H.125). DUOX2 is found in the ducts of the salivary gland, in 
rectal mucosa, all along the gastrointestinal tract including duodenum, colon, and 
cecum, in airway epithelia, and in prostate (for a review, see Bedard K. and Krause K. 
H.125). Induction of DUOX enzymes has been described; DUOX1 is induced in 
response to interleukin (IL)-4 and IL-13 in respiratory tract epithelium, while DUOX2 
expression was induced in response to interferon-γ in respiratory tract epithelium, in 
response to insulin in thyroid cell lines, and during spontaneous differentiation of 
postconfluent Caco-2 cells (for a review see Bedard K. and Krause K. H.125). In 
thyrocytes, DUOX enzymes localize to the apical membrane112,113, although it appears 
that substantial amounts are found intracellularly, presumably in the ER159. When 
heterologously expressed, DUOX enzymes tend to be retained in the ER, and 
superoxide generation can be measured only in broken cell preparations163. This 
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observation led to the discovery of DUOX maturation factors, which are ER proteins 
termed DUOXA1 and DUOXA2164. DUOX maturation factors seem to be crucial in 
overcoming ER retention of DUOX enzymes. Studies on the activation of 
heterologously expressed DUOX2 in membrane fractions indicated that the enzyme 
does not require cytosolic activator or organizer subunits and can be directly activated 
by Ca2+, suggesting that its EF-hand Ca2+-binding domains are functional163; however, 
the p22phox requirement is still a matter of debate. 
A schematic representation of the activation mechanism of all the NOX/DUOX 
family members is reported in fig. 1.6.  
 
 
 
Figure 1.6. Different regulation mechanisms of the members of the NOX/DUOX 
family (figure from Bedard K. and Krause K. H.125). 
 
1. 3. 3. Cytosolic subunits 
The oxidase activity must be strictly regulated, since inappropriate or excessive 
production of superoxide results in inflammatory disorders of surrounding tissues. 
Indeed gp91phox/NOX2 never generates superoxide in resting cells; its activation 
requires interactions with the cytoplasmic factors Rac and the SH3 domain-containing 
proteins p47phox and p67phox 85,165. In stimulated phagocytes these proteins translocate 
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from the cytosol to the membrane, where they interact with cytochrome b558 and thus 
activate gp91phox/NOX2 (fig. 1.7). p67phox contains two Src homology 3 domains (SH3), 
one in the middle of the protein and one near the C-terminus; p47phox is the protein that 
carries all the cytosolic subunits to the membrane. In this process, p47phox translocates to 
the membrane by itself, whereas p67phox is recruited via p47phox166,167: they constitutively 
associates through the interaction between the C-terminal SH3 domain of p67phox and 
the C-terminal proline rich region (PRR) of p47phox168. p47phox binds the PRR domain of 
p22phox through its SH3 domains and this interaction is crucial for the oxidase assembly 
and, consequently, activation169.  
 
 
 
Figure 1.7. Activation mechanism of NOX2/gp91phox (figure from Takeya R. and 
Sumimoto H.128) 
 
In the resting state, to avoid superxide production, the SH3 domains of p47phox are 
normally masked via an intramolecular interaction with an autoinhibitory region 
(AIR)170. In addition to the two SH3 domains, p47phox contains a PX domain in the N-
terminus (fig. 1.8): the PX domain is capable of binding to phosphoinositides but the 
lipid-binding activity is also negatively regulated in resting cells170. Upon cell 
stimulation, p47phox becomes phosphorylated at multiple serines by different protein 
kinases (including protein kinases B and C). Several of these serines are located in the 
AIR sequence171,172. The phosphorylation induces a conformational change in the 
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protein structure which allows both the SH3 and the PX domains to be in an accessible 
state to their membrane targets, p22phox and phosphoinositides, respectively170,173. 
Cooperation of these two interactions, each being indispensable, leads to activation of 
the phagocyte NADPH oxidase170. The main p67phox and p47phox domains are shown in 
fig. 1.8. 
 
 
 
Figure 1.8. The main domains of p67phox and p47phox (figure from Bedard K. and 
Krause K. H.125). 
 
Moreover, Rac is recruited upon cell simulation to the membrane independently of 
p47phox or p67phox174. A crucial event for NOX2 activation is the conversion of Rac from 
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the GDP- to the GTP-binding state. At the membrane, Rac in the GTP-binding state 
directly interacts with p67phox through the binding to the N-terminal domain which 
harbors four TPR motifs and thus the Rac/p67phox complex is probably targeted to 
gp91phox/NOX2 (for a review see Takeya R. and Sumimoto H.128), leading to the 
oxidase activation. In resting cells, this switch is kept “off”, preventing the oxidase from 
producing superoxide. Furthermore, p67phox is known to catalyse the transfer of 
electrons from NADPH to electron acceptor dyes (but not to oxygen)175, so it could be 
directly involved in the electrons transfer process operated by the NADPH oxidase.   
The active oxidase can be formed in a cell-free system reconstituted with the 
purified proteins described above and anionic amphiphiles such as arachidonic acid85. In 
the presence of excess amounts of p67phox and Rac, however, p47phox is not essential for 
the cell-free activation of the oxidase (for a review see Takeya R. and Sumimoto H.128). 
However, p47phox is essential in neutrophils, since its deficiency in patients leads to 
CGD, as it occurs in patients who lacks in p67phox, p22phox or gp91phox/NOX2.  
There is another factor in the oxidase complex, p40phox, which contains PX, SH3, 
and PB1 domains176 and whose function is still unclear. p40phox is supposed to act as an 
adaptor protein which constitutively associates with p67phox in the cytosol of resting 
phagocytes, and enhances superoxide production in stimulated cells130. Differently from 
the other NADPH oxidase subunits, p40phox does not seem to be absolutely essential for 
the oxidase activity, since there is no form of CGD in which it is lacking. Some 
researcher even suggest an inhibitory function of p40phox177. Since p40phox facilitates 
membrane translocation of both p67phox and p47phox, but not that of Rac130, it is likely to 
participate in the activation of the oxidase by regulating membrane recruitment of 
p67phox and p47phox. This stimulatory effect of p40phox is totally dependent on its binding 
to p67phox130, and the binding is mediated through the interaction between the PB1 
domains of both proteins176. It appears that p67phox should function as an oxidase 
activator by using its TPR, PB1, and C-terminal SH3 domains to interact with Rac, 
p40phox and p47phox, respectively. 
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1. 3. 4. Downstream effects of NADPH oxidase and activating stimuli 
NADPH-oxidase-derived ROS exert many downstream effects in the cellular system, 
which include: 
1) alterations in the activity of redox-sensitive protein kinases, such as mitogen-
activated protein kinases (MAPKs) and protein kinases B,C, and D, which may 
occur indirectly following inactivation of tyrosine phosphatases or through direct 
activation; 
2) modifications in the activity of transcription factors, including nuclear factor-kappa B 
(NF-κB), activating protein-1 (AP-1), hypoxia-inducible factor-1 (HIF-1), and 
STATs; 
3) direct effects on enzymes like matrix metalloproteinases (MMPs), receptors, or ion 
channels. 
NADPH oxidases are specifically activated by diverse agonists that evoke the 
activation of cellular signal transduction pathways. Agonists and stimuli relevant to 
myocardial remodelling and heart failure that are also known to activate NADPH 
oxidases include: 
1) G-protein-coupled receptor agonists, e.g. angiotensin II, endothelin-1, and α-
adrenergic agonists100,104,178; 
2) growth factors (for example vascular endothelial growth factor (VEGF)179 and 
plateled-derived growth factor (PDGF)180,181) and insulin182; 
3) cytokines, for example TNF-α 101,183; 
4) mechanical forces184; 
5) hypoxia-reoxygenation185.  
Interestingly, since activation of Rac is inhibited by the HMG-CoA reductase 
inhibitors (for example, statins), inhibition of Rac-requiring NADPH oxidases may be 
one of the many pleiotropic actions of these drugs.  
 
1. 3. 5. NADPH oxidase in hypertrophy and heart failure 
When the heart is subjected to systemic workload, it undergoes structural and functional 
changes which lead to myocytes size increase and wall-thickness and are described as 
left ventricular hypertrophy (LVH). This process can be initially considered as an 
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adaptative response to stress, but if the overload persists, LVH progresses to chronic 
heart failure, with the well known consequences of interstitial fibrosis, chamber 
stiffness, LV dilatation, contractile depression and arrhythmia. Similarly, the heart 
adapts to myocardial infarction by alteration in myocytes, extracellular matrix and 
chamber properties, in a process known as ventricular remodelling. Also in this case, 
the process leads to fibrosis, impaired contraction and arrhythmia. In both the processes, 
an increased activation of the renin-angiotensin-aldosterone system (RAAS) and β-
adrenergic system is involved. 
Reactive oxygen species production has been demonstrated to play a crucial role 
in the onset of both LVH and adverse remodelling post-MI46,186. Moreover, the 
hyperetrophy of isolated cardiomyocytes induced by Angiotensin II, endotelin-1 or 
mechanical forces is reported to involve increased ROS production46. Taking into 
account the role of NADPH oxidase as a ROS-generating system, it is clear the 
involvement of this enzyme in such heart diseases. 
An increasing body of data indicates important roles for NADPH oxidase in LVH 
and CHF, and well established evidence shows that this enzyme is involved in the 
pathophysiology of VSM proliferation, angiotensin II-dependent and low renin 
hypertension, atherosclerosis and angiogenesis, largely through the modulation of 
redox-sensitive signalling pathways187-189. Furthermore, end-stage failing myocardium 
from human CHF patients exhibits increased NADPH oxidase subunit expression and 
activity53,66,67 and, recently, polymorphisms in components of NADPH oxidase were 
reported to be associated with an increased risk of CHF occurring in response to 
cytotoxic therapy190. 
NADPH oxidase subunit expression and activity were found to be increased in 
both cardiomyocytes and endothelial cells in experimental pressure overload LVH in 
guinea-pigs65 and in mice149,191. The role of NADPH oxidases has recently been 
investigated more directly by studies employing NOX2 knock out mice. In a model of in 
vivo cardiac hypertrophy induced by short-term (7-14 days) subpressor infusion of 
angiotensin II, Bendall and colleagues72 found that increases in heart/body weight ratio, 
myocytes area and mRNA expression of ANF and hMHC were all markedly inhibited 
in NOX2-/- mice compared to wild-type controls. This was associated with an absence 
of Angiotensin II-induced increases in LV NADPH oxidase activity in NOX2-/- mice. 
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These data suggest an essential role for the NOX2 oxidase in short-term angiotensin II 
induced cardiac hypertrophy. In keeping with this, angiotensin II-induced signalling and 
hypertrophy of isolated cardiomyocytes were found to be dependent upon NOX2192,193 
while the small GTP-binding protein Rac1 was reported to be involved in isolated 
myocyte hypertrophy induced by endothelin1, angiotensin II or phenylephrine. 
Byrne and co-workers149 studied the effects of aortic constriction, as a model of 
pressure overload, on wild-type and NOX2-/- mice. They found that, in contrast to 
angiotensin II infusion, both morphological LVH and the associated rises in mRNA 
expression of molecular markers such as ANF were similar in NOX2-/- and wild-type 
mice. Interestingly, however, LV NADPH oxidase activity was significantly increased 
by aortic banding not only in wild-type but also in NOX2-/- mice, which was attributed 
to an increased expression of the NOX4 isoform in banded NOX2-/- animals. These data 
suggest that NOX4-derived ROS could contribute to the development of pressure 
overload-induced LVH whereas NOX2 appears indispensable for the response to short-
term angiotensin II infusion.  
Nevertheless, further studies suggest that NOX2 has an important role in the 
development of other aspects of the cardiac phenotype in response to pressure overload. 
Detailed analyses of LV contractile function by echocardiography and LV conductance 
pressure–volume measurements in wild-type and NOX2-/- mice subjected to aortic 
banding showed that NOX2-/- mice were significantly protected against the LV systolic 
and diastolic dysfunction observed in wild-type animals70. This protection against 
contractile dysfunction was also evident in isolated cardiomyocytes. The signal 
transduction pathways through which the above effects of NADPH oxidase may be 
mediated remain to be fully elucidated. Potential redox-sensitive downstream targets 
that have been shown to be activated by NADPH oxidase-derived ROS in other tissues 
include RAS, c-src, the MAPKs, the PI3 kinase (PI3K)/Akt pathway, NF-κB, AP-1, 
HIF-1 and others. Taken together, these data suggest several potential redox-sensitive 
signalling pathways that may be modulated by NADPH oxidase. However, the precise 
pathways activated or inhibited in a NOX isoform-specific manner remain the subject of 
ongoing investigation.  
Another well known effect of ROS its their role in fibrosis, a process which 
involves several aspects such as an increase in fibroblast proliferation, their 
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transformation into matrix-generating myofibroblasts, the expression of pro-fibrotic 
genes and alterations in the balance between the activities of MMPs and tissue 
inhibitors of MMPs (TIMPs). Furthermore, NADPH oxidase has been shown to be 
involved in MMP activation in the vasculature, e.g., in response to mechanical stretch194 
or angiotensin II195. Interestingly, NOX2 also appears to have a pro-fibrotic role in 
pressure overload LVH since NOX2-deficient mice subjected to aortic banding were 
found to have reduced interstitial fibrosis compared to banded wild-type animals70. The 
above results suggest an important role for NOX2-containing NADPH oxidase in the 
development of interstitial cardiac fibrosis. However, the relevant NOX2-expressing 
cell type that is involved remains unclear. NOX4 is also known to be expressed in 
cardiac fibroblasts, but its role in mediating in vivo cardiac fibrosis has not been 
addressed to date.  
An important role for increased oxidative stress in adverse LV remodelling post-
MI is also well recognized. Markers of oxidative stress are elevated post-MI196 and, in 
experimental models, various antioxidant approaches (e.g., probucol, dimethylthiourea 
or genetic manipulation) have been found to ameliorate the adverse remodelling. Post-
MI remodelling was also prevented in mice overexpressing glutathione peroxidase197. 
The benefits of these antioxidant approaches extended to an improvement in contractile 
function and lower mortality. Recently, a role for NOX2 oxidase as a specific source of 
ROS involved in the above effects has been suggested. The expression of the NADPH 
oxidase subunits, NOX2 and p22phox, was found to be increased after experimental MI 
in rats and it was also suggested that the increases correlated with the inflammatory 
phase of tissue repair73. Human myocardium from patients who had died for acute MI 
was also found to exhibit increases in the expression of cardiomyocitic NOX2 and 
p22phox198. Taking into account the great body of studies present in literature, the 
implications of NADPH oxidase in many aspects of cardiovascular disease appear 
evident. The NADPH oxidase-related redox pathways should be completely clarified in 
order to find out new possible therapies for such complex diseases. 
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1. 4. Antioxidant enzymes 
As reported in the § 1. 2., an important line of defence against ROS is represented by 
antioxidant enzymes. In mammalian cells, there are three principal enzymes responsible 
for ROS degradation: superoxide dismutase, which catalyses the dismutation of 
superoxide radical to hydrogen peroxide, and both the glutathione peroxidase and the 
catalase, which catalyse the reduction of H2O2 to water.  
 
1. 4. 1. Cytosolic and mitochondrial superoxide dismutase 
Superoxide dismutases (SODs) are metalloenzymes that catalyse the dismutation of 
superoxide anion to molecular oxygen and hydrogen peroxide199,200. They represent a 
crucial part of the cellular antioxidant defence mechanism. 
Three types of SODs have been described with regard to their metal content: 
copper/zinc (Cu-Zn), manganese (Mn) and iron (Fe) SODs. In humans, the three form 
of SODs are differently distributed in the cytosol (Cu-ZnSOD, also named SOD1), in 
mitochondria (MnSOD, also named SOD2) and in the extracellular space (FeSOD, also 
named SOD3)201. SOD1 is a citosolic homodimeric enzyme of 32 kDa. SOD2 is a 
homotetrameric enzyme of 25 kDa located in the mitochondrial matrix. The Mn2+ ion 
is coordinated to three histidine and one aspartate residues. SOD3 is an extracellular 
homotetrameric enzyme. Extracellular SOD is localised both in the interstitial spaces of 
tissues and in extracellular fluids, accounting for the majority of the SOD activity in 
plasma, lymph and synovial fluid202,203. Sodium cyanide is usually used as an inhibitor 
of cytosolic and extracellular SOD204,205, since it is able to interact with their specific 
metals. The genes for SO1, SOD2 and SOD3 are located in the chromosomes 21, 6 and 
4, respectively. 
The amount of SOD in cellular and extracellular environments is crucial for the 
protection against diseases linked to oxidative stress. Mutation in SOD account for 
approximately 20% of familiar amyotrophic lateral sclerosis (ALS) cases. SOD appears 
to be also a key enzyme in the prevention of other neurodegenerative disorders such as 
Alzheimer’s, Parkinson’s and Huntington’s disease206,207. 
The reaction catalysed by SODs is extremely fast, with a turn over of 2 x 109 M-1 
sec-1 and the presence of sufficient enzymes amounts in cells and tissues typically keeps 
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the concentration of superoxide very low208. When either SOD activity is decreased or 
absent (i.e. SOD mutations) or NO concentration is increased (i.e. iNOS upregulation), 
NO outcompetes SOD for superoxide, resulting in the formation of peroxynitrite. The 
presence of nitrotyrosyne as a “footprint” for peroxynitrite, and hence the prior co-
existence of both superoxide and nitric oxide, has been observed in a variety of 
mediacal conditions, including atherosclerosis, sepsis and ALS208. 
In the heart, MnSOD accounts for about 70% of total SOD activity; this value 
reach the 90% in cardiac myocytes209. Few data are present in literature on SOD activity 
during the progression to heart failure. The behaviour of SOD had been evaluated in 
rodent hearts subjected to hemodynamic overload induced by myocardial infarction or 
aortic constriction. Early after these stimuli, an increase in oxidative stress was followed 
by enhances in GPx1 and SOD activity. Interestingly, when the hearts of these animals 
showed sighs of transition to failure, the activity of SOD was decreased allowing a 
progress to severe heart failure49,196. Unlike these animal models, studies in pathologic 
samples of patients with end-stage heart failure gave conflicting data, showing either 
unchanged myocardial SOD and GPx1 activities 204,205 or a decreased SOD activity210.   
 
1. 4. 2. Catalase 
Catalase is a tetrameric enzyme which catalyses the reduction of one molecule of H2O2 
to H2O (two molecules) and oxidizes a second H2O2 to O2. Being exclusively localized 
in the peroxisomes in mammalian cells, a major role of catalase is likely to remove 
H2O2 produced during α-oxidation of fatty acids in peroxisomes. With the exception of 
rat myocardial cells, catalase is not detectable in the mitochondria211. Catalase effects on 
cytosolic H2O2 must rely on the diffusion of H2O2 into these organelles. Furthermore, 
despite its high turnover number, catalase is not efficient in eliminating low levels of 
H2O2 because it is difficult to saturate with H2O2 and its catalytic cycle requires the 
interaction of two H2O2 molecules with a single active site, which is less likely at low 
H2O2 concentrations212. Therefore, catalase is not expected to play a significant role in 
eliminating low levels of H2O2 produced in response to receptor engagement. 
Nevertheless, recently Kufe and colleagues have shown recently that catalase is 
extensively regulated in responses to H2O2213-217 concentration through the Abelson 
(Abl) family of non receptor tyrosine kinases. The Abl family members are c-Abl and 
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Arg (the product of c-Abl-related gene)218 and they are activated in response to 
oxidative stress. Treatment of cells with H2O2 induces the binding between the protein 
kinase Cδ and c-Abl, followed by phosphorylation and activation of c-Abl217. As a 
matter of fact, activation of c-Abl by H2O2 is attenuated by the protein kinase Cδ 
inhibitor, rottlerlin, and by overexpression of the regulatory domain of protein kinase 
Cδ. Activated c-Abl and Arg appear to regulate catalase. In cells treated with H2O2, c-
Abl and Arg form heterodimers trough a mechanisms which involves the SH3 domain 
of one kinase and the PXXP motif of the other kinase. The resulting dimeric kinases 
then associate with catalase through interaction involving the SH3 domain of the kinase 
and the P293FNP motif of catalase214,215. The binding is independent of the c-Abl kinase 
function as c-Abl (K→R) or Arg (K→R) mutants, which have an inactive kinase, also 
associates with catalase. The bound kinases then phosphorylate catalase at Tyr231 and 
Tyr386 and enhance the catalytic activity of catalase by four- to five fold. The treatment 
with c-Abl inhibitor STI571 is able to attenuate tyrosine phosphorylation of catalase in 
response to H2O2 in MCF-7 cells214. However, mutations on Tyr231 and Tyr386 failed 
to completely abrogate phosphorylation, thus indicating the potential involvement of 
other tyrosines. The significance of the physical interaction between c-Abl/Arg and 
catalase and the subsequent phosphorylation of catalase is supported by the 
demonstration that cells deficient in either c-Abl or Arg exhibit increased H2O2 
levels214. 
The mechanism of catalase regulation by c-Abl and Arg is biphasic in response to 
H2O2 concentrations214: at lower H2O2 levels, c-Abl and Arg phosphorylate and activate 
catalase. If H2O2 concentration increases, c-Abl and Arg dissociate from catalase and 
render catalase susceptible to dephosphorylation by tyrosine phosphatases, resulting in 
decrease of catalase activity.  
Moreover, in another study, Kufe and colleagues showed that catalase is degraded 
through an ubiquitination-dependent processes and that the rate of catalase 
ubiquitination is dependent on c-Abl- and Arg mediated tyrosine phosphorylation216. As 
a matter of fact, Tyr→Phe catalase mutants (Y231F and Y386F) showed a substantially 
decreased ubiquitination level compared with that of wild-type catalase. In concert with 
these results, human 293 cells expressing Y231F or Y386F exhibit attenuated levels of 
reactive oxygen species when exposed to H2O2216. Based on the observations described 
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above, Kufe and colleagues proposed a dual roles model of c-Abl and Arg in catalase 
regulation (fig. 1.9).  
 
 
 
Figure 1.9. The structure of c-Abl and Arg and the regulation mechanism of catalase 
activity. (A) Domain structure of c-Abl and Arg. The N-terminal region, the SH3, the 
SH2 and the SH1 (kinase) domains share about 90% identity. Both the proteins present 
a PXXP domain in the c-terminus, which serves as binding site for the SH3 domains. 
(B) Proposed model for H2O2 concentration-dependent mechanism of catalase activity 
regulation. 
 
In the model, in addition to stimulating catalase activity by inducing catalase 
phosphorylation at lower H2O2 levels, c-Abl and Arg promote catalase degradation in 
the event of uncontrollable H2O2 levels. Thus, at lethal concentrations of H2O2, c-Abl 
and Arg function as pro-apoptotic effectors, as indicated by the fact that cells deficient 
in both the kinases exhibit an attenuated apoptotic response216. 
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1. 4. 3. Glutathione peroxidase 
Glutathione peroxidase (GPx) reduces hydrogen peroxide to H2O through the oxidation 
of reduced glutathione to its disulfide form. GPxs are obligatory tetramers, each 
containing one selenocysteine (Cys-SeH) in its active site. During the catalytic 
mechanism of GPx, the Cys-SeH residue reacts with H2O2 to produce cysteine selenenic 
acid (Cys-SeOH). GSH then binds to the Cys-SeOH and reduces it to Cys- SeH. 
There are at least five types of GPx in mammalian cells. The classical GPx1 is a more 
abundant ubiquitous protein219 and found mainly in the cytosol and in the matrix of 
mitochondria; the gastrointestinal GPx2; the plasma GPx3; the phospholipids 
hydroperoxide GPx4, and the epididymal secretory GPx5220. Mice deficient in GPx1 
develop normally, but exhibit sensitivity to H2O2219,221. 
Kufe and colleagues extended their studies on the role of c-Abl and Arg on 
antioxidant enzymes activation also to GPx1. They found that c-Abl and Arg bind to 
GPx1 through interaction between their SH3 domains and a proline rich region in GPx 
present in the aminoacidic sequence 132–145222. This leads to the GPx1 
phosphorylation at Tyr96 by the kinase complex and to its consequent activation. In 
concert with these findings, inhibition of c-Abl with STI571 in SH-SY5Y cells 
decreases GPx activity; expression of kinase active c-Abl increases GPx activity, 
whereas the dominant negative c-Abl (K→R mutant) has an inhibitory effect. 
Moreover, GPx activity is decreased in c-abl-/- arg-/- mouse embryo fibroblasts (MEF) 
cells compared with wild-type cells222. 
 
 
1. 5. Mitogen activated protein kinases 
The mitogen-activated protein kinase (MAPK) superfamily is a widely distributed 
group of enzymes that has been highly conserved through evolution. There are at least 
three subfamilies of the MAPKs: the extracellular signal-regulated kinases (ERKs), the 
c-Jun N-terminal kinases (JNKs), which are also known as stress-activated protein 
kinases (SAPKs), and the p38- MAPKs223-225. While the ERKs appear to be principally 
involved in anabolic processes (cell growth, division and differentiation), the JNKs and 
p38 MAPKs- related pathways are primarily activated by various environmental 
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stresses: osmotic shock, UV radiation, heat shock, oxidative stress, protein synthesis 
inhibitors, stimulation of FAS, and proinflammatory cytokines such as TNFα and 
interleukin-1 (IL-1)226. Recently, ERK5/big MAPK 1 (BMK1) was identified as the 
novel class of stress activated MAPK. ERK5 is also activated in response to oxidative 
stress and osmotic shock227. 
All MAPKs are proline-directed protein kinases and preferentially phosphorylate 
Ser/Thr residues within a Pro-Xaa-(Ser/Thr)-Pro motif or minimally a Ser/Thr-Pro 
motif. However, such sequences are relatively common within proteins, and other 
determinants of substrate specificity undoubtedly exist. The MAPKs are final 
components of a three-members MAPKs cascade (fig. 1.10).  
 
 
 
Figure 1.10. MAPKs cascade (from Matsuzawa A. and Ichijo H.228) 
 
As shown in the figure, MAPKs are activated by MAPK kinases (MAPKKs, or 
MKKs) which catalyse the ordered dual phosphorylation of a Tyr and a Thr residue 
lying within a Thr-Xaa-Tyr motif of the MAPKs. The identity of the variable (Xaa) 
amino acid helps to define MAPK subfamily membership. Activation of MAPKKs 
involves their phosphorylation on Ser/Thr residues by MAPKK kinases (MAPKKKs). 
The MAPKs cascade is evolutionarily well conserved in all eukaryotic cells. 
ERK, JNK, and p38 have all been shown to be activated in response to oxidant 
injury and therefore they may potentially contribute to influencing cell survival or cell 
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death. In neuron- like PC12 pheochromocytoma cells, nerve growth factor (NGF) 
withdrawal leads to sustained activation of the JNK and p38 MAPK and inhibition of 
ERK, and both effects are required for the induction of apoptosis229. 
Although the idea that ERK and JNK/p38 have opposing functions is still 
generally accepted, recent studies suggest that activations of SAPKs appear to be 
important for cell survival and differentiation. The dynamic balance between the 
magnitude and the duration of both ERK and JNK/p38 activations is a key to 
determining whether a cell will survive or undergo apoptosis. The following is a brief 
description of the three principal members of the MAPKs family, which have been 
particularly implicated in the present study. 
 
ERK  
The best studied MAPK pathway is the ERK1/2 pathway. ERK1/2 is generally 
phosphorylated in response to growth factors and cytokines, and its activation is related 
to the stimulation of tyrosine kinase receptors, which elicits a signalling cascade 
involving Ras activation, recruitment of Raf-1 MAPKKK to the plasma membrane, and 
sequential activation/phosphorylation of MEK1/2 and ERK1/2230. Activated ERK1 and 
-2 phosphorylate various transcription factors and other protein kinases, thereby 
influencing a large variety of cellular processes, such as cell survival, differentiation, 
and cell-cycle regulation. Moreover, oxidative stress leads to substantial activation of 
ERK1/2. Many growth factor (e.g. epidermal growth factor (EGF) and PDGF) 
receptors, which have been shown to undergo phosphorylation in response to oxidative 
insults such as H2O2 and UV irradiation231,232, play an important role in mediating this 
effect. The activation of the growth factor receptor-ERK1/2 pathway by oxidative stress 
is consistent with the observation that low and adequate concentrations of ROS are 
mitogenic233. Although it has been reported that the ERK1/2 pathway contributes to 
cisplatin-induced apoptosis234, ERK1/2 generally can function as a survival and 
antiapoptotic factor following oxidative injury235. 
ERK5, a putative MEK5 target, was cloned as part of a two-hybrid screening that 
used MEK5 as bait227. It is about 90-kDa and it has the specific sequence Thr-Glu-Tyr 
in its phosphorylation loop, like ERK1/2. ERK5/BMK1 can be activated by stress 
stimuli such as oxidative stress, UV irradiation, ischemia, and hyperosmolarity. Several 
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studies have shown that a non receptor tyrosine kinase, c-Src, is redox-sensitive and 
required for activation of ERK5/BMK1236,237. It has been demonstrated that 
ERK5/BMK1 activation contributes to cell proliferation, although its physiological role 
remains to be fully characterized. 
 
JNK and p38 MAPK  
Both JNK and p38, which are stress-activated MAPK family members, are regulated by 
environmental stress and proinflammatory cytokines such as IL-1 and TNFα. JNK is 
activated by various oxidant compounds, such as H2O2, arsenite, cadmium chloride, and 
UV-B radiation235,238,239. Differently from ERK, JNK and p38 have Thr-Pro-Tyr and 
Thr- Gly-Tyr motifs, respectively, as phosphorylation consensus sequence. The p38 
MAPKs are activated by various types of oxidative stress, like JNK-activating oxidants, 
as well as other cellular stress such as osmotic shock, heat shock, and 
lipopolysaccharide235,240,241. Singlet oxygen and NO contribute to activate the p38 
MAPK pathway, which is required for oxidant-induced apoptosis242,243. Specific 
inhibitors of JNK and p38 pathways or expression of dominant-negative mutants for 
JNK and p38 suppressed apoptosis induced by various stresses226. A cell-penetrating 
peptide inhibitor of JNK is an extremely potent neuronal protector in vivo against 
cerebral ischemia and excitotoxicity244. Many studies have show that JNK and p38 have 
a critical role in signal transduction of oxidative stress-induced apoptotic cell death. 
Recent data offer some mechanisms linking ROS and SAPK. Antioxidants and thiol 
reductants, such as N-acetylcysteine and dithiothreitol, and overexpression of 
antioxidative enzymes, such as MnSOD and glutathione S-transferase π (GSTp), can 
block or delay apoptosis. GSTp can interact with JNK to suppress its activation. ROS 
trigger the detachment of JNK from GSTp, and thereby facilitate JNK activation245.  
Hsp70 can inhibit JNK activity and JNK-mediated apoptosis246. JNK- and p38-
mediated phosphorylation of p53, which augments the p53 response, may also play a 
role in their proapoptotic actions247,248. However, the mechanisms by which MAPK 
signalling molecules regulate oxidative stress-induced apoptosis have not yet been 
clearly understood. 
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1. 6. Aim of the study 
The NADPH oxidase is known to play an important role in many cardiovascular 
pathologies such as atherosclerosis, hypertension, hypertrophy and failure187-189. 
Moreover, no convincing data had been reported on the role of the enzyme and its 
activation mechanism in cardiomyocytes undergoing post-ischemic reperfusion injury. 
The aim of the first part of this study was to investigate the level and the activation 
mechanism of NADPH oxidase during post-ischemic reperfusion and to find a link 
between its related ROS production and the switch of a specific redox-sensitive 
pathway. To this purpose, a cellular line of rat embryonic cardiaomyocytes was used for 
simulated ischemia/reperfusion injury experiments to: 
1) investigate the role and the activation mechanism of NADPH oxidase in I/R 
conditions and assess whether NADPH oxidase-derived ROS may be involved in 
the activation of oxidative stress-sensitive MAPKs; 
2) describe the possible role performed by the different members of the MAPK family 
in cell death; 
3) check whether cardiomyocytes damage could be prevented by the use of NADPH 
oxidase (and MAPKs) inhibitor(s). 
As extensively documented in literature, oxidative stress plays a key role in the 
onset of heart failure46-48 and cardiac remodelling51,52. The role of NADPH oxidase in 
ROS production has been documented in human and animal models of cardiac failure 
and myocytes hypertrophy. Moreover, the complete NADPH oxidase-dependent redox 
signalling cascade during heart failure had been incompletely clarified and the 
behaviour of antioxidant enzymes in this condition is still a topic of discussion.  
Notwithstanding these studies, the main data are focused on the left ventricle, which is 
considered the most compromised during heart failure and cardiac remodelling. Given 
that RV function is a predictor of survival in heart failure patients249-251, the 
characterisation of its specific redox-signalling pathway can contribute to a broaden 
insight into the pathophysiological processes involved in the progression toward end-
stage heart failure. Based on these observations, human left and right ventricular 
biopsies from end-stage non-failing and failing donor hearts affected by ischemic, 
dilated and mitochondrial cardiomyopathies were examined with the aims to: 
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1) evaluate the activity status and the activation mechanism of NOX2-containing 
NADPH oxidase in both the heart chambers; 
2) assess the cascade of events triggered by increased NADPH oxidase activity in 
human heart failure; 
3) investigate the mutual relationship between the two ventricles; 
4) describe the activity status of antioxidant enzymes (superoxide dismutase, 
glutathione peroxidase, and catalase) in response to the increased oxidative stress 
and assess whether these changes were equally coordinated in the left and right 
ventricles. 
                                                                                                   EXPERIMENTAL PROCEDURES 
 53
CHAPTER 2 
 
EXPERIMENTAL PROCEDURES 
 
 
 
 
2. 1. Experimental model PART I: simulated ischemia/reperfusion 
injury on H9c2 rat cardiac myoblasts 
 
2. 1. 1. H9c2 rat cardiac myoblast cells culture 
A cellular line of embryonic rat cardiac myoblasts (line H9c2 (2-1), n° 88092904) with 
skeletal muscle properties was used. H9c2 cells were provided from European 
Collection of Cell Cultures (ECACC, Salisbury, UK). Cells were plated at a density of 5 
x 105/ 100 mm plate dishes (Barloworld Scientific Italia s. r. l., Italy) and cultured at 37° 
C in 5% CO2 humidified atmosphere in Dulbecco's Modified Eagles Medium (DMEM, 
Sigma, Italy) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Sigma, 
Italy), 1% L-glutamine, 1% streptomycin and 1% penicillin (Sigma, Italy). Cells were 
passaged regularly at sub-confluence (70-80%) and re-cloned periodically, to maintain 
differentiated characteristics, before experimental procedures. 
 
2. 1. 2. Ischemia/reperfusion simulation 
H9c2 cells were seeded the day before the experiment, at an established concentration, 
into 35 mm culture dishes for fluorometric measurements of ROS production, into 96-
well plates, for LDH release and MTT assays, or into petri dishes, for all the other 
procedures (Barloworld Scientific Italia s.r.l., Italy). Cells were maintained in normoxic 
condition till the beginning of the experiment. Simulated ischemia was obtained as 
previously reported252  with minor modifications. Briefly, at the time of experiment, 
cells were washed with PBS (Sigma, Italy) and the culture medium was replaced with a 
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low volume of substrate-free medium (serum-free, glucose-free and sodium pyruvate-
free DMEM, DME base, Sigma, Italy), supplemented with 4.3 g/L NaHCO3, 1% L-
glutamine, 1% streptomycin and 1% penicillin. Cells were incubated in an anaerobic 
Plexiglas box (Billups-Rothenberg Inc., CA, USA), hermetically sealed, which was 
saturated with 95% N2 and 5% CO2, and incubated at 37° C for 24 h. The volume of 
hypoxic medium used was the minimum volume required to coat the cellular monolayer 
for the prevention of cellular dehydration during the ischemic period. Simulated 
ischemia was followed by a simulated “reperfusion” period, during which the cells were 
exposed to normoxic fresh culture medium at 37° C for 60 min in the absence and in the 
presence of the following drugs: 10 µM diphenyleneiodonium chloride (DPI, Sigma, 
Italy), a flavoprotein inhibitor, and 100 µM apocynin (Sigma, Italy), both used as 
NADPH oxidase inhibitors, 10 µM rotenone (Sigma, Italy), a mitochondrial oxidase 
complex I inhibitor, 100 µM oxypurinol (Sigma, Italy), a xanthine oxidase inhibitor, 20 
µM SP600125 (Sigma, Italy), a selective JNK inhibitor compound, and 10 mM 4,5-
dihydroxy-1,3-benzene-disulfonic acid (tiron, Sigma, Germany), a superoxide 
scavenger. For each experiment, control H9c2 cardiac cells were incubated at 37° C in 
5% CO2 humidified atmosphere in complete culture medium for the time of simulated 
ischemia and reperfusion. 
 
 
2. 2. Sample preparation 
 
2. 2. 1. Cell lysis 
At the end of “reperfusion” cells were washed twice with ice-cold PBS, harvested with 
a 0.25% Trypsin-EDTA solution and lysed in an ice-cold lysis buffer (10 mM Tris-HCl, 
pH 7.4 containing 150 mM NaCl, 2 mM EGTA, 2 mM DTT), supplemented with fresh 
10 mg/L leupeptin(Sigma, Italy), 10 mg/L aprotinin(Sigma, Italy), 1 mM PMSF (Sigma, 
Italy) and phosphatase inhibitor cocktail (Sigma, Italy). Cells were maintained on ice 
for 30 min and then sonicated with a Vibra Cell sonicator (Sonics & Materials Inc., 
Danbury, CT, USA) three times on ice, for an overall 15 sec time period. Samples were 
centrifuged using an Eppendorf Centrifuge 5804 R (Eppendorf, Italy) for 5 min at 960 x 
g (4° C) and the supernatants (homogenates) were assayed for superoxide production, 
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and lipid peroxidation. To evaluate NOX2/gp91phox protein expression and p47phox 
translocation, membrane and cytosolic fractions of the homogenates were separated by 
ultracentrifugation with an L8-70M Ultracentrifuge (Beckman Coulter Inc., Fullerton; 
CA, USA) for 60 min at 100000 x g (4° C) and used for immunoblotting. The “purity” 
of membrane and cytosolic fractions were confirmed by markers of enzyme activities as 
previously described. Western blotting for MAP kinases was performed on 
homogenates centrifuged for 10 min at 20800 x g (4° C) on the Eppendorf Centrifuge 
5804 R (Eppendorf, Italy). 
 
2. 2. 2. Protein content evaluation 
Protein concentration was measured by bicinchoninic acid (BCA) protein assay (Pierce, 
Italy). The assay is based on the reduction of Cu2+ to Cu1+ by proteins in an alkaline 
medium (Biuret reaction) and the colorimetric detection of Cu1+ cations by 
bicinchoninic acid. The purple-coloured product is formed by the chelation of two 
molecules of BCA with one cuprous ion and absorbs at 562 nm (absorbance can be 
measured between 550 and 570 nm). The reaction is also strongly influenced by the 
presence of any of cysteine, tyrosine or tryptophan residues in the amino acid sequence 
of the protein.  
Every assay was performed on a 96 wells multiwell and the 570 nm absorbance of 
the samples was read on a Microplate Reader model 550 (Bio-RAD Laboratories, Italy) 
spectrophotometer. For each assay, protein concentration of the samples was 
extrapolated from a standard curve obtained with different concentrations of bovine 
serum albumin (BSA, Sigma, Italy). 
 
 
2. 3. Fluorometric measurements of intracellular ROS production in 
adherent H9c2 cells 
Intracellular ROS content in H9c2 cells was evaluated measuring the oxidation of 10 
µM 2', 7'-dihydrodichlorofluorescein diacetate (H2DCF-DA, Invitrogen, Italy) to 
fluorescent dichlorofluorescein, as described previously253. Dichlorofluorescein 
diacetate is a cell permeable non fluorescent compound whose acetate groups are 
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removed by intracellular esterases once it has entered the cell. The product of de-
acetylation, known as dichlorofluorescein (DCF), is a charged form of the dye, not able 
to pass the plasma membrane. Oxidation of DCF by hydrogen peroxide occurs within 
the cell and leads to the formation of a fluorescent probe which absorbs at 438 nm and 
emits at 535 nm (fig. 2.1). 
 
 
 
Figure 2.1. Mechanism of action of H2DCFDA. 
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For this analysis, cells were plated on 6-well plates and exposed to simulated 
ischemia/reperfusion as previously described. 10 min before the end of reperfusion, 
cells were washed in PBS and re-suspended in a 2 ml/well of PBS containing 10 µM 
H2DCF-DA. After 10 min of incubation at 37° C in the dark, cells were washed with 
PBS, lysed in RIPA buffer (50 mM Tris-HCl pH 7.5, containing 150 mM NaCl, 1% 
Triton X-100 and 2mM EGTA) and fluorescence of samples was immediately analyzed 
with Fluoroskan Ascent Fluorometer (Thermo Electron Corporation, Finland). Positive 
and negative controls were also evaluated. The positive control consisted of cells treated 
for 30 min with 200 µM H2O2 (to allow a significantly high ROS production) which did 
not undergo to simulated ischemia/reperfusion. The negative controls consisted of RIPA 
buffer with 10 µM H2DCFDA in the absence/presence of oxidase inhibitors and tiron 
(to avoid autofluorescence phenomena). DCF fluorescence was expressed as arbitrary 
units (A.U.) and normalized to total protein content. 
 
 
2. 4. Luminometric evaluation of superoxide production in cell lysates 
Superoxide production was assessed by lucigenin-enhanced chemiluminescence. 
Experiments were performed on a luminometer (Lumat LB 9507 EG&G Berthold) in 
20mM Tris-HCl, pH 7.2, with 100 µg of cell lysate/tube and a non redox–cycling 5 µM 
lucigenin.  
 
 
 
Figure 2.2. Lucigenin oxidation and its chemiluminescent product. 
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In the presence of superoxide radical lucigenin is oxidized to a chemiluminescent 
product which emits light at 470 nm (fig. 2.2). 
Superoxide generation was measured at room temperature in the absence or in the 
presence of substrates of the most important oxidase complexes: 300 µM NADPH 
(Sigma, Italy), 5 mM succinate (Sigma, Italy) or 1 mM xanthine (Sigma, Italy), 
substrates, respectively, of NADPH oxidase, mitochondrial oxidase complex I and 
xanthine oxidase. Measurements were also taken after a 10 min pre-incubation with the 
oxidase inhibitors: 10 µM DPI, 50 µM rotenone and 100 µM oxypurinol. Moreover, 20 
mM tiron was also used as negative control. The signal of a blank buffer (consisting of 
the reaction mixture without oxidases substrates) was subtracted from each reading. 
Superoxide production was expressed as mean arbitrary light units (MLU) per mg 
protein per sec over a 10 min period.  
 
 
2. 5. Lipid peroxidation assay on cell lysates 
Lipid peroxidation is a well-established marker of oxidative stress injury. The 
peroxidation of polyunsaturated fatty acid leads to the production of a series of instable 
compounds, and eventually to the formation of malondialdehyde (MDA) and 4-
hydroxyalkenals. Hence, MDA content can be assessed as a marker of oxidative stress. 
MDA content was determined using a "Biooxytech LPO-586 Assay" kit (Oxis 
International Inc, Prodotti Gianni, Italy). The assay is based on the reaction between one 
molecule of MDA and two molecules of the chromogenic reagent N-methyl-2- 
phenylindole (R1), provided by the manufacturer, at 45° C in the presence of HCl (fig. 
2.3). HCl allows the condition to selectively measure MDA, without 4-hydroxyalkenals. 
The reaction product absorbs at 586 nm. 
In particular, 100 µg of samples, reagent R1 and 37% HCl were mixed and 
incubated at 45° C for 60 min. After this step (acid hydrolysis), samples were 
centrifuged at 950 x g for 10 min (4° C), transferred into spectrophotometric cuvettes 
with a 1 cm optical path length and their 586 nm absorbance was measured on a 
Ultrospec 2000 spectrophotometer (Pharmacia Biotech, NJ, USA). MDA concentration 
for each sample was extrapolated from a standard curve obtained with a 10 mM 
standard MDA, provided as an acetal by the kit and freshly diluted in H2O to a 20 µM 
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solution before each experiment. Sample blanks were also assessed to subtract the 
sample background. MDA concentration was expressed as nmol/mg protein. 
 
 
 
Figure 2.3. Scheme of the reaction between MDA and reagent R1. 
 
 
2. 6. Western blotting on cell lysates 
Equal protein amounts of cellular homogenates or membrane and cytosolic fractions (35 
µg) for every sample were diluted in 2X reducing Laemmli buffer (0.5 M Tris-HCl, pH 
6.8, glycerol, 10% SDS, 2-β-mercaptoethanol, bromophenol blue) and boiled at 90° C 
for 5 min. A HL-60 cell lysate (sc-2209, Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) was used as a positive control for the detection of NOX2. Samples were separated 
on 12% SDS-PAGE using a Tris/Glycine/SDS running buffer (BioRad, Italy) in the 
presence of a Precision Plus Protein Prestained Dual Colour molecular weight marker 
(BioRad, Italy). Samples were transferred to Immobilion-P transfer membranes 
(Millipore, MA, USA), pre-equilibrated in Tris/Glycine buffer (BioRad, Italy), using a 
transferring apparatus (Biorad, Italy). After blocking with 5% (w/v) BSA in 0.1% (v/v) 
TBS-Tween, membranes were incubated overnight at 4° C with one the following 
antibodies: 
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1) goat polyclonal anti-gp91phox (1:1000, sc-5827), and anti-p47phox antibodies (1:1000, 
sc-7660) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), for NADPH oxidase 
subunities detection; 
2) rabbit monoclonal antibodies that specifically recognize the phosphorylated active 
forms of MAP kinases (1:1000, #9938 Phospho- MAPK family kit, Cell Signaling 
Technology, MA, USA); 
To ensure equal protein loading, membranes were washed 3 times with 0.1% (v/v) TBS-
Tween and then stripped with a Restore Western blotting Stripping buffer (Pierce, Italy) 
for 40 min at 37° C. After a blocking with 5% (w/v) BSA in 0.1% (v/v) TBS-Tween, 
membranes were incubated with one the following antibodies: 
1) mouse monoclonal anti-α-actin antibody (1:1000, sc-32251, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), for NOX2; 
2) anti-β-tubulin antibody (1:1000, sc-5274, Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), for p47phox; 
3) rabbit polyclonal anti-JNK (1:1000, sc-571), anti-ERK (1:1000, sc-93) and anti-p-38 
(1:1000, sc-535) antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), for 
phospho-MAP kinases; 
After washing in 0.1% (v/v) TBS-Tween, membranes were incubated for 60 min 
at room temperature with anti-goat (1: 3000, sc-2020), anti-rabbit (1:10000, sc-2004) or 
anti-mouse (1:5000, sc-2005) peroxidase-conjugated antibodies (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), diluted in 1% (w/v) BSA in 0.1% (v/v) TBS-
Tween, were used. Immunoreactive bands were detected by chemiluminescence 
Immobilion Western ERP Substrate (Millipore, MA, USA) and quantified by 
densitometric analysis using a Gel Logic 2200 Imaging System and a Kodak Molecular 
Imaging Software (Kodak, CT, USA). MAP kinases activation was expressed relative to 
their total protein content. NOX2 and p47phox protein expression were expressed relative 
to α-actin and β-tubulin protein content, respectively. p47phox membrane translocation 
was expressed relative to its cytosolic content 
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2. 7. Immunocytochemical localization of NOX2 protein expression 
and p47phox membrane translocation in H9c2 adherent cells  
In order to perform immunofluorescence staining, H9c2 cardiac muscle cells were 
grown on coverslips (VWR, Strasbourg, France) in 35 mm culture dishes (Barloworld 
Scientific Italia s.r.l., Italy). After ischemia and reperfusion, cells were washed with 
PBS, fixed with 3% (v/v) paraformaldheyde/PBS and incubated for 20 min at 4° C. 
Cells were permeabilized with 0.1% (v/v) Triton-X-100/TBS and blocked with PBS 
containing 1% BSA and 10% horse serum for 60 min at room temperature. The 
coverslips were incubated overnight at 4° C with 100 µl of a 1:50 goat-anti-gp91phox or a 
goat-anti-p47phox antibody (sc-5827 and sc-7660, respectively, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), dissolved in TBS containing 3 % BSA. To 
avoid evaporation of TBS, the multiwell was sealed up with parafilm. Coverslips were 
washed three times in 0.1% Triton-X-100/TBS and once with 0.1% BSA in 0.1% 
Triton-X-100/TBS, and then a 1:400 fluorescein-isothiocyanate (FITC)-conjugated anti-
goat secondary antibody (green fluorescence, Fluka, Switzerland) diluted in 0.1% (v/v) 
Triton-X-100/TBS containing 1% BSA was added for 60 min at room temperature. 
After several washes in 0.1% Triton-X-100/TBS in the dark, cell nuclei were 
stained with 5 µl/ml of a propidium iodide solution (red fluorescence, Fluka, 
Switzerland) diluited in 0.1% Triton-X-100/TBS. Coverslips were aspirated dry, sealed 
with glass slides in the presence of Gel Mount (Sigma, Italy), to avoid the bleaching of 
the probe and observed by a TCS-SP5 confocal microscopy (Leica Microsystems, 
Germany), using a 488 nm argon ion laser line for FITC excitation.  
 
 
2. 8. Cell viability assays on H9c2 cells 
 
2. 8. 1. MTT assay 
To evaluate the cytotoxic effect of the inhibitors used during post-ischemic reperfusion, 
MTT assays were performed on H9c2 normoxic control cells254. The rational behind 
this approach is that MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
                                                                                                   EXPERIMENTAL PROCEDURES 
 62
bromide) is reduced by mitochondrial reductases to purple formazan (fig. 2.4), which 
absorbs between 500 and 600 nm depending on the buffer used. The reaction takes 
place only in living cells with functional mitochondria and active reductases, therefore 
the amount of formazan can be considered an indirect marker of cellular viability.  
Experiments were performed into 96-well plates. After 24 h incubation at 37° C in 
5% CO2 humidified atmosphere in complete medium, cells were washed twice with 
PBS. Cells were exposed to fresh culture medium and incubated for 60 min at 37° C in 
5% CO2 humidified atmosphere in complete medium in the absence or in the presence 
of 10 µM DPI (Sigma, Italy), 100 µM apocynin (Sigma, Italy), 10 µM rotenone (Sigma, 
Italy), 100 µM oxypurinol (Sigma, Italy), 20 µM SP600125 (Sigma, Italy) and 10 mM 
tiron (Sigma, Germany). 
 
 
 
Figure 2.4. MTT reduction to formazan. 
 
Since some of these compounds were dissolved in dimethyl sulphoxide (DMSO) 
the same amount of this solvent was used to treat cells and to evaluate its possible toxic 
effects. Cells were washed with PBS and incubated with 100 µl/well of a 0.5 mg/ml 
MTT solution dissolved in DMEM without red phenol for 120 min at 37° C in the dark. 
100 µl of a lysis buffer containing 20% SDS and 50% N-N- dimethylformammide were 
added to each well. After incubation over night at 37° C, absorbance at 470 nm was 
measured on a Microplate Reader model 550 (Bio-RAD Laboratories, Italy) 
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spectrophotometer. MTT reduction in treated cells was expressed as percentage relative 
to control cells without either inhibitors or DMSO.  
 
2. 8. 2. Lactate dehydrogenase release assay 
Lactate dehydrogenase (LDH) release from cells with a damaged membrane is a well 
established marker of cell necrotic death. LDH release was determined through the 
CytoTox-ONE Homogeneous Membrane Integrity Assay (Promega, Italia s. r. l., Italy). 
The assay is based on the reaction catalysed by diaphorase, which consists in the 
conversion of resazurin dye into fluorescent resorufin using NADH as electron donor 
(fig. 2.5). The source of NADH is represented by LDH, the enzyme which converts 
lactate into pyruvate using NAD+ as an oxidizing agent.  
 
 
 
Figure 2.5. Scheme of the reactions used for LDH release assay.  
 
Hence, the production of resorufin is proportional to the amount of LDH in the 
sample. Lactate, NAD+, resazurin and diaphorase were provided with the kit. The 
coupled reactions are shown in fig. 2.5. Experiments were performed into a 96-well 
plate. After simulated ischemia and reperfusion, cells were equilibrated at 22° C for 5 
min. The CytoTox-ONE reagent was added directly to the culture medium in a 1:1 
proportion for each well and then cells were incubated at 22° C for 10 min in the dark. 
Fluorescence signal was measured with a Fluoroskan Ascent Fluorometer (Thermo 
Electron Corporation, Finland), using excitation and emission wavelengths equal to 544 
nm 590 nm, respectively. For each experiment a buffer blank, and a positive control 
were prepared. The blank solution, constituted by 1:1 culture medium and assay 
reagent, was used to avoid interferences due to the LDH amount contained into FBS or 
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to pyruvate contained into DMEM. The positive control, constituted by cells lysed with 
1% Triton-X-100 and assay reagent, was used to obtain the highest LDH release level of 
this specific cell line. 
After subtraction of the buffer blank signal, LDH release in each sample was 
expressed as the percentage of LDH release and related to the total LDH content 
measured in the positive control. 
 
2. 8. 3. Trypan blue dye exclusion assay 
Cell viability was determined by Trypan blue (TB) dye exclusion assay. After simulated 
ischemia/reperfusion, cells were gently harvested with a 0.25% Trypsin-EDTA solution 
(Sigma, Italy) and the cellular suspension was mixed with a 0.4% TB solution (Sigma, 
Italy), in a 1:1 proportion. Cellular suspension was observed under a phase-contrast 
inverted microscope. The viable cells with intact plasma membranes, which were able 
to exclude the dye, and the necrotic cells with damaged plasma membranes, that were 
marked by the dye, were counted using a hemocytometer. Cell viability was expressed 
as percentage of viable cells over the total counted. 
 
 
2. 9. Statistical analysis 
All values are expressed as mean ± standard error mean (S.E.M.). Comparisons were 
performed using Analysis of Variance (ANOVA) followed by a Tukey-Kramer multiple 
comparison test. Correlation coefficient r was obtained using a linear (Pearson) 
correlation test. Probabilities of p < 0.05 were considered statistically significant.  
 
 
2. 10. Experimental model PART II: human biopsies of end-stage 
failing hearts 
All studies were performed on left and right ventricular biopsies of human non failing 
and end-stage failing hearts, in collaboration with the Departments of Experimental 
Medicine and Pathology, at “La Sapienza” University of Rome, and the Department of 
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Preclinical and Clinical Pharmacology, at the University of Florence. Experiments were 
conformed to the Declaration of Helsinki and institutional ethical regulations and they 
were carried out after informed consent of relatives (in the case of autopsy samples) or 
patients. Non failing (NF) donor hearts, which were unsuitable for transplantation for 
technical reasons, were used as controls. Explanted failing hearts were obtained from 
patients undergoing transplantation for end-stage heart failure secondary to ischemic 
heart disease or idiopathic dilated cardiomyophaties. In the case of maternally inherited 
cardiomyophaties, myocardial tissues were obtained after death (Family #1, Patient #1) 
or heart transplant (Family #2, Patient #2 and #3). 
Immediately after explant, myocardial tissue samples were snap-frozen in liquid 
nitrogen-chilled isopentane for protein, RNA analysis, and biochemistry. All tissues 
were stored at -80° C. Sections stained with hematoxylin-eosin and Masson Trichrome 
stain, were obtained from each sample for morphological examination prior to each 
experiment. Histologic slides from both failing and non failing hearts were observed 
under light microscopy. Myocyte hypertrophy was a common finding in all failing 
hearts, associated with variable degrees of interstitial fibrosis, graded from mild (+ 1) to 
severe (+ 3) on a semi quantitative basis. According to the results of histologic 
examination, myocardial samples with minimal amounts of fibrosis and devoid of 
inflammatory infiltrates were selected for molecular and biochemical studies. In 
addition, atrial natriuretic factor (ANF), and myosin heavy chain (MHC)-α and -β 
isoforms mRNA expression, molecular markers of cardiac hypertrophy, were evaluated 
by quantitative RT-PCR on both NF and failing hearts using the Platinum SYBR Green 
qPCR Super Mix- UDG (Invitrogen). The clinical characteristic of the patient are 
reported below in the text (§ 2. 10. 1, § 2. 10. 2, § 2. 10. 3) and in the tables (2. 1, 2. 2 
and 2. 3). These evaluations were accomplished at the Department of Experimental 
Medicine and Pathology, at “La Sapienza” University of Rome. 
 
2. 10. 1. Human biopsies of end-stage failing hearts - 1st study - 
Experiments on the role of NADPH oxidase in the biochemical pathways related to the 
progression of heart failure were carried out on biopsies of both left and right ventricles 
from non failing (n = 6; no cardiac medication) and failing hearts secondary to ischemic 
heart disease (n = 7) or idiopathic dilated cardiomyophaties (n = 7). All patients affected 
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by IHD and DCM had New York Heart Association class IV heart failure, with a mean 
LV ejection fraction of 21.5 ± 1.14 and a mean pulmonary artery pressure of 34.2 ± 3.8 
(see Table 2. 1).  
 
 NF IHD DCM 
Total number 6 7 7 
Sex (M/F) 4/2 6/1 4/3 
Age (range) 44 (38-52) 52 (41-67) 45 (33-62) 
LVEF (%)  26 ± 1.89 17 ± 0.38 
CI (l/min/m2)  2.37 ± 0.23 1.8 ± 0.07 
PAP (mm Hg)  39.2 ± 4.87 29.2 ± 5.36 
PCWP (mm Hg)  25.2 ± 2.92 21 ± 5.36 
RAP (mm Hg)  17 ± 5.79 10.6 ± 4.78 
NYHA  IV IV 
Diuretics - 7 7 
Digoxin - 0 0 
Antiarrhythmics - 3 2 
ACE-I - 7 7 
Β-blockers - 7 7 
Nitrates - 4 0 
HMGCoA-Inh - - - 
ANF/rRNA 18S 1.04 ± 0.013 10.83 ± 1.06 11.93 ± 1.1 
MHC-α/rRNA 18S 1.30 ± 0.04 0.057 ± 0.004 0.03 ± 0.007 
MHC-β/rRNA 18S 1.36 ± 0.12 0.04 ± 0.007 0.46 ± 0.03 
 
Table 2. 1. Clinical characteristics of the donor patients (1st study). 
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2. 10. 2. Human biopsies of end-stage failing hearts -2nd study – 
Experiments on the role of NADPH oxidase-dependent antioxidant enzymes activation 
during the progression to heart failure, were carried out on biopsies of both left and 
right ventricles from non failing (n = 5; no cardiac medication) and failing hearts 
secondary to IHD (n = 7) or DCM (n = 5).  
 
 NF IHD DCM 
Total number 5 7 5 
Sex (M/F) 4/1 6/1 4/1 
Age (range) 44 ± 2.1 39 (30-60) 60 (53-69) 
LVEF (%)  23 ± 4.8 20 ± 2.5 
CI (l/min/m2)  2.4 ± 0.2 1.8 ± 0.05 
PAP (mm Hg)  38 ± 3.2 29 ± 5.4 
PCWP (mm Hg)  24 ± 3 21 ± 5.4 
RAP (mm Hg)  15 ± 4.2 10.5 ± 2.3 
NYHA  III/IV III/IV 
Diuretics - 7 5 
Digoxin - 0 1 
Antiarrhythmics - 2 1 
ACE-I - 7 5 
Β-blockers - 7 5 
Nitrates - 4 0 
HMGCoA-Inh - 2 0 
ANF/rRNA 18S 1.03 ± 0.001 12.4 ± 1.05 12.3 ± 0.98 
MHC-α/rRNA 18S 1.30 ± 0.03 0.06 ± 0.01 0.04 ± 0.002 
MHC-β/rRNA 18S 1.36 ± 0.2 0.06 ± 0.02 0.54 ± 0.05 
 
Table 2. 2. Clinical characteristics of the donor patients (2nd study). 
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All patients had New York Heart Association class III/IV heart failure, with a mean LV 
ejection fraction of 21.5 ± 1.14 and a mean pulmonary artery pressure of 34.2 ± 3.8. 
Clinical characteristics of the three groups are shown in Table 2. 2. 
 
2. 10. 3. Human biopsies of end-stage failing hearts - 3rd study - 
Experiments on the role of NADPH oxidase redox signalling during the progression to 
heart failure in patients affected by maternally inherited cardiomyopaties were 
performed only on left ventricular tissues obtained from 2 families with MIC (n = 3)15. 
The number of clinical biopsies was restricted because of the difficulty to get tissues 
from such a rare type of pathology. In addition, samples from patients with end-stage 
heart failure secondary to ischemic heart disease (n = 9) or idiopathic dilated 
cardiomyopathy (n = 4) were used, in which metabolic disorders (including diabetes) 
were ruled out on the basis of clinical records. Non failing heart samples were obtained 
from donor hearts unsuitable for transplantation for technical reasons (n = 4) and, within 
2 h from death, from pediatric patients who died for non cardiac causes in whom 
mitochondrial disease was excluded on the basis of histologic, histochemical, and 
respiratory chain enzyme studies. Clinical characteristics of the 3 groups are reported in 
Table 2. 3. 
 
 NF MIC IHD DCM 
Total number 8 3 9 4 
Sex (M/F) 4/4 3/0 6/3 4/0 
Age (range) 21 (1 month-44) 18 (5-26) 59 (45-67) 45 (33-48) 
LVEF (%) NA 12 ± 4.04 26 ± 7.2 23 ± 4.6 
ANF/rRNA 18S 1.06 ± 0.007 8.95 ± 1.92 10.83 ± 1.92 11.93 ± 4.45 
MHC-α/rRNA 18S 1.20 ± 0.04 0.06 ± 0.01 0.06 ± 0.02 0.03 ± 0.01 
MHC-β/rRNA 18S 1.20 ± 0.05 0.05 ± 0.01 0.46 ± 0.05 0.05 ± 0.01 
 
Table 2. 3. Clinical characteristics of the donor patients (3rd study). 
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2. 11. Sample preparation 
 
2. 11. 1. Tissue homogenation 
Left and right ventricular samples from non failing and failing hearts were differently 
homogenized in ice-cold 20 mM Tris-HCl, pH 7.4, for lucigenin chemiluminescence 
assay and lipid peroxidation assay, or in ice-cold 20 mM Hepes pH 7.2 containing 1 
mM EGTA, 210 mM mannitol, 70 mM sucrose, for Western blotting and enzymatic 
activity assays. Both homogenation buffers were supplemented with 10 mg/L leupeptin, 
10 mg/L aprotinin, 0.2 mM PMSF and phosphatase inhibitor cocktail. After three times 
sonication on ice for an overall 15 sec time period, samples were centrifuged for 10 min 
at 20800 x g (4° C), for Western blotting and CAT activity assays, or for 10 min at 960 
x g (4° C), for the other assays, on the Eppendorf Centrifuge 5804 R (Eppendorf, Italy). 
Heart homogenate aliquots were also separated into soluble (cytosolic) and membrane 
fractions by ultracentrifugation for 60 min at 100000 x g (4° C) on the L8-70M 
Ultracentrifuge (Beckman Coulter Inc., Fullerton; CA, USA) and used for 
immunoblotting to detect NOX2/gp91phox protein expression and p47phox membrane 
translocation.  
 
2. 11. 2. Protein content evaluation 
Protein concentration was measured by bicinchoninic acid (BCA) protein assay (Pierce, 
Italy), as previously described (§ 2. 2. 2.). 
 
 
2. 12. Luminometric evaluation of superoxide production in tissue 
homogenates 
Superoxide production was assessed by lucigenin-enhanced chemiluminescence, as 
previously described (§ 2. 4.). Experiments were performed on a luminometer (Lumat 
LB 9507 EG&G Berthold) in 20mM Tris-HCl, pH 7.2, with 100 µg of tissue 
homogenate and a non redox–cycling 5 µM lucigenin. 
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Superoxide generation was measured at room temperature in the absence or in the 
presence of substrates of the most important oxidase complexes: 300 µM NADPH 
(Sigma, Italy), 5 mM succinate (Sigma, Italy) or 1 mM xanthine (Sigma, Italy). 
Measurements were also taken after a 10 min pre-incubation with the oxidase inhibitors: 
20 µM DPI, 50 µM rotenone, 100 µM oxypurinol, 100 µM Nω-nitro-L-arginine methyl 
ester hydrochloride (L-NAME, Sigma, Italy) or 20 mM tiron. The signal of a blank 
buffer (consisting of the reaction mixture without oxidases substrates) was subtracted 
from each reading. Superoxide production was expressed as mean arbitrary light units 
(MLU) per mg protein per sec over a 10 min period.  
 
 
2. 13. Lipid peroxidation assay on tissue homogenates  
MDA content was measured using a "Biooxytech LPO-586 Assay" kit (Oxis 
International Inc, Prodotti Gianni, Italy) as previously described (§ 2. 5.). 
 
 
2. 14. Western blotting on tissue homogenates 
Equal protein amounts of tissue homogenates or membrane and cytosolic fractions (35 
µg) for every sample were separated on 12% SDS-PAGE and transferred to 
Immobilion-P transfer membranes (Millipore, MA, USA), as previously described (§ 2. 
6.). After blocking with 5% (w/v) BSA in 0.1% (v/v) TBS-Tween, membranes were 
incubated overnight at 4° C with one the following antibodies: 
1) goat polyclonal anti-gp91phox (1:500, sc-20782), and anti-p47phox (1:2000, sc-14015) 
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), for NADPH oxidase 
subunities detection; 
2) rabbit monoclonal antibodies that specifically recognize the phosphorylated active 
forms of MAP kinases (1:1000, #9938 Phospho-MAPK family kit, Cell Signaling 
Technology, MA, USA); 
3) rabbit polyclonal anti-SOD2 (1:1000, sc-30080) and anti-GPx1/2 (1:1000, sc-30147) 
or goat polyclonal anti-CAT (1:1000, sc-34282) antibodies (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), for antioxidant enzymes detection. 
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To ensure equal protein loading, membranes were washed 3 times with 0.1% (v/v) 
TBS-Tween and then stripped with a Restore Western blotting Stripping buffer (Pierce, 
Italy) for 40 min at 37° C. After a blocking with 5% (w/v) BSA in 0.1% (v/v) TBS-
Tween, membranes were incubated with one the following antibodies: 
1) anti-β-tubulin antibody (1:1000, sc-5274, Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), for NOX2 and for p47phox; 
2) rabbit polyclonal anti-JNK (1:1000, sc-571), anti-ERK (1:1000, sc-93) and anti-p-38 
(1:1000, sc-535) antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), for 
phospho-MAP kinases; 
3) rabbit polyclonal anti-GAPDH antibody (1:5000, sc-25778, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), for antioxidant enzymes. 
The membranes examined for CAT were stripped with Stripping buffer and 
incubated with monoclonal anti-p-Tyr antibody (1:1000, sc-7020, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), which specifically recognizes phosphorylated 
tyrosines. 
After washing in 0.1% (v/v) TBS-Tween, membranes were incubated for 60 min 
at room temperature with anti-goat (1: 3000, sc-2020) and anti-rabbit (1:10000, sc-
2004) peroxidase-conjugated antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), diluted in 1% (w/v) BSA in 0.1% (v/v) TBS-Tween, were used. Immunoreactive 
bands were detected by chemiluminescence Immobilion Western ERP Substrate 
(Millipore, MA, USA) and quantified by densitometric analysis using a Gel Logic 2200 
Imaging System and a Kodak Molecular Imaging Software (Kodak, CT, USA). MAP 
kinases activation was expressed relative to their total protein content. NOX2 and 
p47phox protein expression were expressed relative to α-actin and β-tubulin protein 
content, respectively. p47phox membrane translocation was expressed relative to its 
cytosolic content. SOD2, GPx and CAT protein expression was expressed relative to 
GAPDH protein content. 
                                                                                                   EXPERIMENTAL PROCEDURES 
 72
2. 15. Enzymatic activity assays on tissue homogenates 
 
2. 15. 1. Catalase activity assay 
Catalase (CAT) activity was evaluated with spectrophotometrical measurements of 
H2O2 dismutation. The reaction mixture contained 100 mM phosphate buffer, pH 6.8, 
and 70 µg of sample homogenates. After the addition of 10 mM H2O2, change in optical 
density of H2O2 at 240 nm was recorded for 30 sec at 25° C with the Ultrospec 2000 
spectrophotometer (Pharmacia Biotech, NJ, USA). A quartz cuvette with a 0.5 cm 
optical path length was used. A molar extinction coefficient for H2O2 (ε240) of 43.6 M-1 
cm-1 was used. The ∆E associated to the kinetic of H2O2 dismutation was used to 
evaluate CAT activity through the Lambert-Beer equation. The average value of three 
measurements was calculated. Enzymatic activity was expressed as µmol/min/mg 
protein. 
 
2. 15. 2. Glutathione peroxidase activity assay 
Glutathione peroxidase (GPx) catalyses the oxidation of reduced glutathione (GSH) to 
GSSG, using an organic peroxide as electron acceptor. Its activity can be indirectly 
measured through a reaction coupled with glutathione reductase (GR), which reduces 
GSSG using NADPH as electron donor and producing NADP+. The reaction is shown 
in fig. 2.6. 
 
 
 
Figure 2.6. Coupled reactions of GPx and GR. 
 
Hence, the decrease in NADPH concentration can be related to GPx activity. The 
reaction mixture contained 100 mM phosphate buffer, pH 7.4, 0.5 mM EDTA, pH 7.6, 1 
mM NaN3, 0.25 mM NADPH, 2.25 mM GSH, 1 U/ml GR and 70 µg of sample 
homogenates. After the addition of 0.24 mM tert-butil hydroperoxide (Sigma, Italy), the 
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organic peroxide which triggers the reaction, change in optical density of NADPH at 
340 nm was recorded for 2 min at 25° C with the Ultrospec 2000 spectrophotometer 
(Pharmacia Biotech, NJ, USA). A quartz cuvette with a 0.5 cm optical path length was 
used. A molar extinction coefficient for NADPH (ε340) of 6.22 x 103 M-1 cm-1 was used. 
The ∆E associated to the kinetic of NADPH concentration decrease was used to 
evaluate GPx activity through the Lambert-Beer equation. The average value of three 
measurements was calculated. Enzymatic activity was expressed as nmol/min/mg 
protein. 
 
2. 15. 3. Superoxide dismutase activity assay 
Total superoxide dismutase (SOD) activity was evaluated using the Chemical 
Superoxide Dismutase Assay kit (Cayman Chemical, Ann Arbor, Michigan). The assay 
uses a tetrazolium salt for the detection of superoxide anion generated by xanthine 
oxidase and hypoxanthine. In the presence of superoxide anion, the tetrazolium salt is 
oxidised with the formation of the formazan dye, whose amount increases as SOD 
concentration in the sample decreases. The reaction is shown in fig. 2.7. 
 
 
 
Figure 2.7. Reactions used for measurements of Mn-SOD activity. 
 
One unit of SOD is defined as the amount of enzyme needed to obtain 50% 
dismutation of superoxide radical. The reaction was performed in a 96 well multiwell, 
according to the manufacturer protocol. The assay mixture comprised 50 mM Tris-HCl, 
pH 8, 10 µg of sample homogenates and a solution of tetrazolium salt (the radical 
detector). Specific Mn-SOD activity was obtained by the addition of 1 mM sodium 
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cyanide to the samples in order to inhibit the relative amount of cytosolic Cu/Zn-SOD. 
After incubation at 25° C for 30 min in the dark, xanthine oxidase was added to each 
well, as reported by the manufacturer protocol. The average value of three 
measurements was calculated after 15 min incubation with xanthine oxidase at 25° C in 
the dark. Sample absorbance was measured on a Microplate Reader model 550 (Bio-
RAD Laboratories, Italy) using a 450 nm filter. SOD activity for each sample was 
extrapolated from a standard curve obtained with a standard SOD solution provided 
with the kit. The Mn-SOD activity was obtained by subtracting the Cu/Zn-SOD activity 
from the total SOD activity and it was expressed as µmol/min/mg protein.  
 
2. 15. 4. Citrate syntase activity assay 
Citrate synthase catalyses the production of citrate from oxaloacetate with the reduction 
of acetyl-CoA to CoA-SH. The subsequent reaction between CoA-SH and 5, 5'- 
dithiobis (2-nitro-benzoic acid) (DTNB, Sigma, Italy) leads to the production of 5-thio-
2 nitrobenzoic acid (TNB). Therefore, the increase in TNB concentration can be 
considered an indicator of citrate synthase activity. The reaction is shown in fig. 2.8. 
 
 
 
Figure 2.8. Reactions used for the evaluation of Citrate synthase activity. 
 
The reaction mixture contained 100 mM Tris-HCl, pH 8, 100 µM DTNB, 50 µM 
acetyl-CoA, 250 µM potassium oxaloacetate and 10 µg of sample homogenates. Change 
in optical density of TNB at 412 nm was recorded for 2 min at 25° C with the Ultrospec 
2000 spectrophotometer (Pharmacia Biotech, NJ, USA). A quartz cuvette with a 1 cm 
optical path length was used. A molar extinction coefficient for TNB (ε412) of 13.6 x M-
1 x cm-1 was used. The ∆E associated to the kinetic of TNB concentration increase was 
used to evaluate Citrate synthase activity through the Lambert-Beer equation. The 
average value of three measurements was calculated. Enzymatic activity was expressed 
as µmol/min/mg protein. 
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2. 16. Statistical analysis 
All values are expressed as mean ± standard error mean (S.E.M.). Comparisons were 
performed using Analysis of Variance (ANOVA) followed by a Tukey-Kramer multiple 
comparison test, for three groups analysis, or unpaired test followed by two tails 
comparison test, for two groups analysis. Correlation coefficient r was obtained using a 
linear (Pearson) correlation test. Probabilities of p < 0.05 were considered statistically 
significant.  
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CHAPTER 3 
 
RESULTS 
 
 
 
 
3. 1. PART I: Role of NADPH oxidase in simulated ischemia and 
reperfusion injury 
 
3. 1. 1. Evaluation of possible cytotoxic effects of the inhibitors 
To avoid possible cytotoxic effects due to the inhibitors used during reperfusion, MTT 
assays were performed on normoxic control H9c2 cells not treated and treated for 60 
min with all the drugs. Since some inhibitors were dissolved in DMSO, the possible 
cytotoxic effect of the solvent was also evaluated. The level of MTT reduction observed 
in treated cells, expressed as percentage relative to non treated cells, was similar to the 
one observed in non treated cells (data not shown). Hence, no significant cytotoxic 
effects were observed depending neither to the inhibitors used nor to DMSO.  
 
3. 1. 2. Intracellular ROS increase 
Cells subjected to simulated I/R showed a significant increase in intracellular ROS 
production, as revealed by H2DCF-DA fluorescence intensity measurements compared 
to normoxic controls (fig. 3.1). To determine the source of ROS generation we 
examined the effects of DPI, a flavoprotein inhibitor, and apocynin, both commonly 
used as NADPH oxidase inhibitors125, of rotenone, a mitochondrial oxidase complex I 
inhibitor, and of oxypurinol, a xanthine oxidase inhibitor. As shown in fig. 3.1, DPI and 
apocynin treatments induced a significant decrease in fluorescence, although the 
difference in DPI and apocynin concentration must be taken into account. Albeit not 
sufficient to completely restore the conditions of normoxic control cells, both 
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compounds reduced ROS production to a value similar to that obtained with the 
superoxide scavenger tiron. Rotenone and oxypurinol had no effect on I/R-induced ROS 
generation. 
 
 
 
Figure 3.1. Effects of specific inhibitors of oxidase systems on intracellular ROS 
production in H9c2 cardiac muscle cells exposed to simulated ischemia and reperfusion. 
DCF fluorescence is expressed as arbitrary units (A. U.) normalized to cellular protein 
content. Values are means ± S.E.M.; DPI and apocynin (Apo), inhibitors of NADPH 
oxidase; rotenone (Rote), inhibitor of mitochondrial oxidase complex I; oxypurinol 
(Oxy), xanthine oxidase inhibitor; tiron, superoxide scavenger, used as a positive 
control. * p < 0.05, ** p < 0.01 Vs control (normoxic condition); †† p < 0.01 Vs I/R; n = 
6. 
 
3. 1. 3. NADPH oxidase activity 
To confirm that simulated I/R-induced ROS production was mainly attributable to the 
activation of NADPH oxidase, superoxide production was measured by lucigenin 
chemiluminescence in the absence and in the presence of specific oxidase substrates. 
Neither succinate nor xanthine, substrates of mitochondrial oxidase complex I and of 
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xanthine oxidase, respectively, were able to induce any increase in O2·¯ production in 
I/R cells (fig. 3.2 A).  
 
 
Figure 3.2. (A) Superoxide production in I/R H9c2 homogenate in response to several 
substrates and (B) NADPH-dependent superoxide production in I/R cells in the absence 
or presence of oxidase inhibitors detected by lucigenin chemiluminescence. Results are 
expressed as MLU/sec normalized to protein content. Values are means ± S.E.M.; 
NADPH, NADPH oxidase substrate; succinate, mitochondrial oxidase complex I 
substrate; xanthine, xanthine oxidase substrate. MLU, mean arbitrary light units. Rote, 
rotenone; Oxy, oxypurinol. † p < 0.05, †† p < 0.01 and ††† p < 0.001Vs I/R; n = 6. 
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By contrast, significantly higher O2·¯ generation was detected in I/R cells in the 
presence of NADPH compared to I/R cells without substrate (fig. 3.2 A). The increase 
of NADPH dependent superoxide production was significantly inhibited by DPI and 
tiron (fig. 3.2 B), but was unaffected by rotenone or oxypurinol, supporting the 
hypothesis of NADPH oxidase as a major source of O2·¯ in cells exposed to simulated 
I/R. 
 
3. 1. 4. NADPH oxidase activation mechanism 
To elucidate the mechanisms underlying NADPH oxidase activation in cells subjected 
to simulated I/R, we analyzed the expression of the catalytic subunit NOX2/gp91phox by 
Western blot and immunofluorescence. As shown in fig. 3.3 A, immunoblotting of 
NOX2 membrane protein expression with a goat polyclonal antibody, widely used by 
other authors255-257 gave two different bands that migrated at a position of 
approximately 55–65 kDa. These bands presumably represented unglycosylated 
NOX2198, while the band at around 80 kDa, corresponding to glycosylated NOX2, was 
not detected. Notwithstanding the molecular properties of NOX2 detected by the 
antibody, it is evident that both bands are more intense in I/R samples relative to the 
control, thus suggesting an effective over-expression of NOX2 protein after I/R. DPI 
addition had no effect on NOX2 expression. 
The increase in NOX2 expression was further confirmed by immunofluorescence 
(fig. 3.3 B). In control H9c2 cells confocal images showed NOX2 localized in the 
plasma membrane and in the cytosol, including the perinuclear region (fig. 3.3 B-a). 
After simulated I/R, NOX2 labelling appeared more intense and showed a vesicular or 
granular pattern in all these compartments, (fig. 3.3 B-b), which was not modified by 
DPI treatment (fig. 3.3 B-c). 
To assess whether NADPH oxidase activation in cells exposed to simulated I/R 
was also attributable to a p47phox over-expression and/or membrane translocation, which 
is likely to modulate oxidase activation65,66,100,258, we undertook immunofluorescence 
staining. As shown in fig. 3.4 A, p47phox expression was enhanced in I/R H9c2 
compared to control cells; moreover, the cellular localization of the fluorescent probe 
appeared increased in the cytosol and especially in the plasma membrane. 
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Figure 3.3. Changes in NOX2/gp91phox protein expression in H9c2 cardiac muscle cells 
subjected to simulated ischemia and reperfusion in the absence and in the presence of 
DPI. (A) Representative immunoblot of NOX2/gp91phox (top) and densitometric 
quantification of membrane protein expression relative to α-actin protein expression 
(bottom) expressed as fold increase relative to control. HL-60 cell lysate was used as a 
positive control for the detection of NOX2/gp91phox. Values are means ± S.E.M.; * p < 
0.05 Vs control; n = 6. (B) Confocal images of (a) control, (b) ischemic-reperfused and 
(c) DPI treated H9c2 cells. 
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Figure 3.4. p47phox membrane translocation in H9c2 cardiac muscle cells following 
simulated ischemia and reperfusion in the absence and in the presence of DPI. (A) 
Immunofluorescence of (a) control, (b) ischemic-reperfused and (c) DPI treated H9c2 
cells. (B) Representative immunoblots of p47phox protein expression of membrane and 
cytosolic fraction of H9c2 cardiac muscle cells (top). Densitometric quantification of 
the ratio of membrane to cytosolic protein expression of p47phox (bottom). Values are 
means ± S.E.M. ** p < 0.01 Vs control; †† p < 0.01 Vs I/R; n = 6. 
 
Treatment with DPI resulted in a decreased p47phox immunofluorescence staining, 
which was mainly evident in the sarcolemma, suggesting a change in p47phox 
distribution and supporting the hypothesis of a p47phox translocation from the cytosol to 
plasma membrane after simulated I/R. To confirm these data we analyzed p47phox 
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content in the membrane and cytosolic fractions by Western blotting. The fig. 3.4 B 
shows a significantly higher membrane/cytosolic ratio of p47phox in I/R cells than in 
control. DPI treatment abolished this increase (fig. 3.4). These results point out that, in 
our experimental conditions, the increase in NADPH oxidase activity is due not only to 
NOX2 overexpression but also to the membrane translocation of the cytosolic subunit 
p47phox. 
 
3. 1. 5. NADPH oxidase-related redox signalling: lipid peroxidation 
Lipid peroxidation resulting from oxidative stress has been implicated in cell death. 
 
 
 
Figure 3.5. Lipid peroxidation, assessed by intracellular MDA content evaluation, in 
H9c2 cardiac muscle cells subjected to simulated ischemia followed by reperfusion in 
the absence and in the presence of DPI. Values are expressed as fold increase relative to 
control. * p < 0.05 Vs control; † p < 0.05 Vs I/R; n = 6. 
 
To test whether simulated I/R-mediated NADPH oxidase activation was involved 
in lipoperoxidative cell damage we measured MDA cell content, as an indirect index of 
ROS activity259. Measurements were performed in the absence and in the presence of 
DPI. Accordingly to the differences observed in ROS production, MDA levels were 
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significantly increased in cells subjected to simulated I/R. In the presence of DPI, MDA 
content was significantly reduced, as we observed with tiron treatment (fig. 3.5), 
suggesting that NADPH oxidase-derived ROS are the main responsible for lipid 
peroxidation in I/R cells. 
 
3. 1. 6. NADPH oxidase-related redox signalling: MAPKs activation 
To elucidate the signal transduction pathway involved in simulated I/R injury, we 
evaluated the phosphorylation level of the three principal members of the MAPK family 
(p38, ERK and JNK) by Western blotting.  
 
 
 
Figure 3.6. Effect of DPI (A, B, C) and of SP600125 (C) on MAPKs activation induced 
by simulated ischemia and reperfusion in H9c2 cardiac muscle cells. Representative 
immunoblots for p-p38 (A), p-ERK (B) and p-JNK (C) (top) and respective total protein 
in H9c2 homogenate (bottom). Densitometric quantification of the ratio of 
phosphorylated/total MAPKs protein content expressed as fold activation relative to 
control. SP600125, selective JNK inhibitor compound. * p < 0.05 and ** p < 0.01 Vs 
control; † p < 0.05 Vs I/R; n = 6. 
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Cells exposed to simulated I/R showed no significant changes in the p38 
phosphorylation status (expressed as p-p38/p38 ratio) relative to control cells (fig. 3.6 
A). By contrast, ERK (p-ERK/ERK ratio) and JNK (p-JNK/JNK ratio) phosphorylation 
was significantly increased (1.7-fold, p < 0.01; and 2-fold, p < 0.05; both Vs control; fig. 
3.6 B and C). In order to verify a possible link between these events and NADPH 
oxidase activation, we analyzed ERK and JNK phosphorylation in the presence of DPI. 
DPI treatment significantly decreased only the p-JNK/JNK ratio; a similar result was 
obtained with the selective JNK inhibitor, SP600125260, which reduced the p-JNK/JNK 
ratio to control level (fig. 3.6). 
In agreement with this effect, a positive correlation (r = 0.74, p < 0.01) was found 
between NADPH oxidase-derived superoxide production and JNK activation. 
 
3. 1. 7. NADPH oxidase-related redox signalling: cell viability and LDH 
release 
As determined with the Trypan blue dye exclusion assay (fig. 3.7 A), the viability of 
cells subjected to I/R was decreased by 26% relative to the control. Accordingly, the 
fraction of total LDH released in the culture medium (fig. 3.7 B) by I/R cardiomyoblasts 
was significantly increased (1.6-fold, p < 0.05 Vs control). All these effects were 
significantly reduced by the treatment with the two unrelated inhibitors DPI or 
SP600125; in fact, cell treatment with both inhibitors resulted in the same protective 
effect against simulated I/R induced cell death. Moreover, the percentage of both viable 
cells and LDH released showed a significant correlation with JNK phosphorylation (r = 
-0.73, p < 0.01 and r = 0.75, p < 0.01, respectively). 
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Figure 3.7. Effect of DPI and of SP600125 on cell death of H9c2 cardiac muscle cells 
exposed to simulated ischemia and reperfusion. Cell death was evaluated by Trypan 
blue dye exclusion assay (A) and by LDH released into the culture medium (B). For 
Trypan blue assay results are expressed as percentage of viable cells over the total cell 
counted. For LDH release, results are expressed as percentage of total LDH content. ** 
p < 0.01 Vs control; † p < 0.05 and †† p < 0.01 Vs I/R; n = 6. 
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3. 2. PART II - 1st STUDY: NADPH oxidase-dependent redox 
signalling in end-stage human failing hearts secondary to IHD and 
DCM 
 
3. 2. 1. NADPH oxidase activity 
Superoxide production was measured by lucigenin chemiluminescence in the absence or 
presence of NADPH, succinate or xanthine. Both succinate and xanthine provided a 
minimal O2·¯ production in the RV and LV homogenate, which did not differ between 
non failing (NF) and failing hearts (data not shown). In the presence of NADPH, 
significantly higher O2·¯ generation was detected in non failing LV compared to non 
failing RV (240.14 ± 8.1 MLU/sec/mg protein Vs 160 ± 10.6 MLU/sec/mg protein, 
respectively). Diseased LV and RV specimens exhibited a marked increase in O2·¯ 
production compared to NF controls. In particular, the increase in superoxide generation 
was less marked, although statistically significant, in failing LVs (IHD 1.38-fold, p < 
0.001 Vs NF; DCM 1.23-fold, p < 0.05 Vs NF), while a 2-fold and 1.65-fold increase in 
NADPH-dependent O2·¯ production was observed in the RVs from IHD and DCM 
hearts (p < 0.001 Vs NF) (fig. 3.8 A). Interestingly, in RV samples from failing hearts, 
O2·¯ production, attributable to NADPH oxidase activity, was positively related to the 
respective pulmonary arterial pressure (PAP; r = 0.86, p = 0.0014) (fig. 3.8 B). To 
investigate the sources of superoxide production, experiments were performed in the 
presence of potential ROS-generating systems inhibitors. NADPH-dependent O2·¯ 
production was virtually abolished by tiron, thus confirming O2·¯ as a major source of 
ROS detected in our experimental conditions. In both RV and LV samples from failing 
hearts, NADPH-dependent O2·¯ generation was significantly decreased by DPI, but was 
unaltered by L-NAME, the nitric oxide syntase inhibitor, rotenone, or oxypurinol, 
supporting the idea that a phagocyte-type NADPH oxidase is likely to be a major source 
of O2·¯ in the human failing heart (fig. 3.8 C, D). 
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Figure 3.8. (A) NADPH-dependent O2·¯ production in human non failing (NF) and 
failing RV (open bars) and LV (solid bars) hearts detected by lucigenin 
chemiluminescence. MLU, mean arbitrary light units; * p< 0.05 Vs NF; ** p<0.01 Vs 
NF. n = 6 NF and n = 7 failing ventricles from hearts with IHD or DCM. (B) 
Correlation between pulmonary artery pressure (PAP) and right ventricle NADPH-
dependent superoxide production of IHD and DCM; n = 5 for each group. (C and D) 
Effect of specific inhibitors of oxidase systems on NADPH-dependent O2·¯ production 
in human failing RV (C) and LV (D). Data are presented as mean ± S.E.M. and 
expressed as percentage of the value measured in the absence of inhibitors (NoI). *** p 
< 0.001 Vs NoI. 
 
3. 2. 2. NADPH oxidase activation mechanism: the role of p47phox 
To elucidate the mechanisms underlying the increased NADPH oxidase activity in the 
failing myocardium, experiments were designed to investigate NOX2/gp91phox and its 
regulatory subunit p47phox. NOX2 protein expression, assessed by Western blotting in 
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the same RV and LV homogenates used for measurements of NADPH-dependent 
superoxide production, did not differ between NF and failing hearts (data not shown). 
 
 
 
Figure 3.9. p47phox protein expression and membrane translocation in human RV and 
LV. (A) Representative immunoblotting of p47phox protein expression in the 
homogenates and in the membrane and cytosolic fractions of non failing (NF) and 
failing RV and LV. (B) Densitometric quantification of p47phox homogenate protein 
expression relative to β-tubulin protein expression. (C) Densitometric quantification of 
the membrane/cytosolic ratio of p47phox protein expression. Data are calculated as mean 
± S.E.M. and expressed as fold increase of failing Vs non failing hearts. RV, open bars; 
LV, solid bars; homo, homogenate; mem, membrane; cyt, cytosolic; n=6 non failing, 
NF and n=7 failing ventricles from hearts with IHD or DCM; * p < 0.05, ** p < 0.01, 
and *** p < 0.001 Vs NF. 
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By contrast, p47phox was significantly over-expressed in RV and, more markedly, 
in LV homogenates from failing hearts compared to NF, regardless of the aetiology of 
the disease (IHD or DCM) (fig. 3.9 A, B). p47phox membrane content was higher in non 
failing LV than in non failing RV (1.29 ± 0.12 Vs 0.82 ± 0.10, respectively, p < 0.001). 
On the other hand, the increment in membrane/cytosolic ratio of p47phox was 
significantly higher in the failing RV membrane fraction (IHD 1.99-fold, p < 0.001 Vs 
NF; DCM 1.64- fold, p < 0.001, Vs NF) compared to the failing LV (IHD 1.32-fold, p < 
0.001 Vs NF; DCM 1.22-fold, p < 0.05, Vs NF) (fig. 3.9 A and C). The prominent role 
of p47phox membrane translocation as a mechanism for NADPH oxidase activation was 
further supported by the positive correlation between NADPH oxidase activity and 
sarcolemmal fraction of p47phox, both in RV (r = 0.76, p = 0.001) and in LV specimens 
(r = 0.79, p = 0.001).  
 
 
 
Figure 3.10. (A) MDA content in human RV (open bars) and LV (solid bars). n=6 non 
failing, NF, and n=7 failing ventricles from hearts with IHD or DCM. * p < 0.05; ** p < 
0.01 Vs NF. (B and C) Correlations between NADPH-dependent superoxide production 
and MDA content in human RV (B) and LV (C). NF (▲), DCM (●), IHD (♦); n=5 for 
each group. 
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3. 2. 3. NADPH oxidase-related redox signalling: lipid peroxidation 
Accordingly to the differences observed in ROS production, MDA levels were 
significantly increased in RV and LV samples from failing hearts (fig. 3.10 A, previous 
page). In addition, MDA content was positively correlated to NADPH-dependent 
superoxide generation in both ventricles (fig. 3.10 B and C, previous page) (RV: r = 0.8, 
p = 0.0004; LV: r = 0.7, p = 0.0026). 
 
3. 2. 4. NADPH oxidase-related redox signalling: MAPKs activation 
To investigate the possible activation of redox-sensitive MAPKs, we evaluated the 
phosphorylation level of JNK, ERK and p38. JNK phosphorylation status did not 
change in failing ventricles compared to the respective NF controls (fig. 3.11 A). 
Conversely, fig. 3.11 B shows a significant increase in ERK1/2 phosphorylation 
level in RV from IHD (2.96-fold, p < 0.001 Vs NF) and, to a lesser extent, from DCM 
(1.80-fold, p < 0.01 Vs NF); in LV specimens, a significant increase (1.58-fold, p < 0.01 
Vs NF) was observed only in IHD. Furthermore, ERK activation positively correlated 
with NADPH oxidase activity in both ventricles (RV: r = 0.83, p = 0.0001; LV: r = 
0.62, p = 0.014). p38 as well showed a significant enhancement in the phosphorylation 
status both in RV and LV specimens from failing myocardium compared to respective 
controls (fig. 3.11 C). The increase in p38 phosphorylation was comparable in the RV 
and LV, obtained from either IHD (RV 3.90-fold, p < 0.001 Vs NF; LV 3.92-fold, p < 
0.001 Vs NF) or DCM hearts (RV 2.21-fold, p < 0.05 Vs NF; LV 2.85-fold, p < 0.001 
Vs NF). Interestingly, MDA content in failing hearts showed a significant correlation 
with p38 phosphorylation status in both RV (r = 0.95; p = 0.0001) and LV specimens (r 
= 0.86; p = 0.0001). Overall, these findings suggest that ERK phosphorylation is 
associated with increased NADPH oxidase activity, and support a role for elevated 
MDA levels in p38 activation, in agreement with previous reports in cellular models259. 
                                                                                                                                          RESULTS 
 91
 
 
Figure 3.11. Activation of p-38 (A), ERK1/2 (B) and JNK (C) in human RV and LV. 
Every panel shows representative immunoblotting for p-p38, p-ERK1/2 and p-JNK and 
relative total protein in non failing and failing ventricle homogenates (top). The 
densitometric quantification of the phosphorylated/total MAPKs protein content ratio 
(bottom) is also reported; RV, open bars; LV, solid bars. n=6, non failing, NF and n=7 
failing ventricles from IHD or DCM. * p < 0.05; ** p < 0.01; *** p < 0.001 Vs NF. 
 
3. 2. 5. Relationship between left and right ventricles 
The results shown so far suggest the occurrence of a similar sequence of biochemical 
events in both ventricles from failing hearts. Furthermore, a significant correlation was 
found between the values measured in LV and RV of the same hearts for all relevant 
steps of the oxidative stress pathway (fig. 3.12), in particular NADPH-dependent O2·¯ 
production (A), MDA content (B), p38 (C) and ERK1/2 activation (D). 
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Figure 3.12. Oxidative stress pathway. Correlations between: RV and LV NADPH-
dependent O2·¯generation (A), RV and LV MDA content (B), RV and LV p-38 
activation (C) and RV and LV ERK 1/2 activation (D). NF (▲), DCM (●) and IHD (?) 
ventricles. n=5 for each group. 
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3. 3. PART II – 2nd STUDY: NADPH oxidase-dependent antioxidant 
enzymes activation in end-stage human failing hearts secondary to 
IHD and DCM 
 
3. 3. 1. NADPH oxidase activity 
Our previous results demonstrated an involvement of NADPH oxidase in human failing 
hearts regardless of the aetiology of the disease (IHD or DCM)53. For this reason, in this 
study we did not distinguish samples from ischemic and non ischemic cardiomyopathy.  
 
 
 
Fig. 3.13: (A) NADPH-dependent superoxide production in human RV (open bars) and 
LV (solid bars) from non failing (NF) and failing hearts (F) detected by lucigenin 
chemiluminescence. *** p < 0.001 Vs NF; ††† p < 0.001 Vs RV failing hearts. n = 5 NF 
and n = 12 failing ventricles from hearts with IHD or DCM. Data are presented as mean 
± S.E.M. and expressed as fold increase relative to NF. (B) Correlation between left and 
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right ventricle NADPH-dependent superoxide production of the same failing and non 
failing hearts; n =5 for each group. MLU, mean arbitrary light units. (C) Effect of 
specific oxidases inhibitors on NADPH-dependent superoxide production in RV and 
LV from human failing hearts. Data are presented as mean ± S.E.M. and expressed as 
percentage of the value measured in the absence of inhibitors (NoI). *** p < 0.001 Vs 
NoI. 
 
We confirmed a higher and significant NADPH-dependent O2·¯ production in new 
samples of diseased LV and RV from human failing heart compared to new samples of 
NF controls. In particular, a 2.23-fold increase (p<0.001 Vs NF) was observed in the RV 
from failing hearts, while in failing LV the increase (1.64-fold) was less marked, 
although statistically significant (fig. 3.13 A). In addition, a significant correlation was 
found between the values observed in LV and RV of the same failing heart (fig. 3.13 B) 
(r=0.7811; p=0.0076). NADPH dependent superoxide production was greatly inhibited 
in both failing RV and LV samples only by the NADPH oxidase inhibitor DPI (85%; 
p<0.001) and by the O2·¯ scavenger tiron (90%; p<0.001) (fig. 3.13 C), whereas it was 
unaffected by the xanthine oxidase inhibitor, oxypurinol, and reduced non significantly 
by NOS inhibitor (L-NAME) and by the inhibitor of the mitochondrial electron 
transport chain, rotenone. 
 
3. 3. 2. Antioxidant enzymes defences: catalase 
We performed a systematic analysis of antioxidant enzymes by measuring protein levels 
as well as activities of CAT, GPx and Mn-SOD, in failing and non failing ventricular 
specimens. As shown in fig. 3.14, protein levels (fig. 3.14 A) of CAT showed a trend 
for a decrease in their expressions that did not reach statistical significance between NF 
and failing RV and LV. By contrast, the enzymatic activity was significantly enhanced 
in both ventricles from failing hearts and, in particular, diseased LV exhibited a marked 
increase compared to NF control (fig. 3.14 B) (RV 1.76-fold, p<0.05; LV 3.04-fold, 
p<0.001; F Vs NF). Interestingly, the level of CAT activity in failing LV was also 
significantly higher than that observed in failing RV (RV:17.13 ± 1.29 µmol/min/mg 
protein; LV: 23.88 ± 1.50 µmol/min/mg protein p<0.005). 
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Fig. 3.14: Catalase (CAT) protein expression and catalytic activity in human RV (open 
bars) and LV (solid bars) from non failing and failing hearts. (A) Representative 
immunoblot (top) and densitometric quantification (bottom) of CAT protein expression 
relative to GAPDH expression. (B) Enzymatic activity of CAT detected by a 
spectrophotometric method. Data are presented as mean ± S.E.M. and expressed as fold 
increase relative to NF. * p < 0.05 Vs NF; *** p < 0.001 Vs NF. n = 5 NF and n = 12 
failing ventricles from hearts with IHD or DCM. 
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Fig. 3.15: Glutathione peroxidase (GPx) protein expression and catalytic activity in 
human RV (open bars) and LV (solid bars) from non failing and failing hearts. (A) 
Representative immunoblot (top) and densitometric quantification (bottom) of GPx 
protein expression relative to GAPDH expression. (B) Enzymatic activity of GPx 
detected by a spectrophotometric method. Data are presented as mean ± S.E.M. and 
expressed as fold increase relative to NF. ** p < 0.01 Vs NF. n = 5 NF and n = 12 
failing ventricles from hearts with IHD or DCM. 
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3. 3. 3. Antioxidant enzymes defences: glutathione peroxidase 
Immunoblotting of GPx protein expression, detected with a commercially available 
rabbit polyclonal antibody, gave two different bands that, in unboiled and boiled 
samples, migrated, respectively, to a position of approximately 92 kDa and, of 22 kDa, 
representing GPx homotetramer and monomer. The intensity of both bands from failing 
RV and LV appeared unchanged relative to the control (fig. 3.15 A, previous page). 
Densitometric analysis of 22 kDa band confirmed that no differences in protein 
expression exists between failing and NF RV and LV. Instead, GPx activity was 
significantly increased in failing RV and LV (fig. 3.15 B, previous page) with a similar 
increment in their activities relative to NF hearts (RV 1.52-fold, p<0.01; LV 1.65-fold, 
p<0.01; F Vs NF). 
 
3. 3. 4. Antioxidant enzymes defences: mitochondrial superoxide dismutase 
Mn-SOD is the mitochondrial isoenzyme that accounts for 90% of total SOD activity in 
heart . Mn-SOD protein expression was unaffected in both failing ventricles, compared 
with NF ones (fig.3.16 A). Mn-SOD enzymatic activity, normalized to citrate synthase 
activity as a marker of mitochondrial mass, appeared significantly decreased in failing 
RV and LV (fig.3.16 B). 
These findings suggest that a similar adaptive response occurs in human failing 
LV and RV and that the increase or the decrease in antioxidant enzymes activities is 
largely attributable to post-translational modifications induced by oxidative stress. 
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Fig. 3.16: Mn-Superoxide Dismutase (Mn-SOD) protein expression and catalytic 
activity in human RV (open bars) and LV (solid bars) from non failing and failing 
hearts. (A) Representative immunoblot (top) and densitometric quantification (bottom) 
of Mn-SOD protein expression relative to GAPDH expression. (B) Enzymatic activity 
of Mn-SOD detected by a spectrophotometric method and related to Cytrate synthase 
activity, a marker of mitochondrial mass. Data are presented as mean ± S.E.M. and 
expressed as fold increase relative to NF.* p < 0.05 Vs NF; *** p < 0.001 Vs NF. n = 5 
NF and n = 12 failing ventricles from hearts with IHD or DCM. 
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3. 3. 5. Tyrosine-phosphorylation in failing hearts 
Recent studies from Cao and co-workers reported that in response to increased oxidative 
stress the Abl family of mammalian non-receptor tyrosine kinases, including c-Abl and 
Arg, were activated. This activation was associated with a phosphorylation of CAT and 
GPx with a subsequent stimulation of their activity214,222.  
To determine if catalase activity was regulated by (Tyr) phosphorylation, the same 
membrane used to analyze CAT protein expression was reblotted with the anti-Tyr(P) 
antibody. Interestingly, as shown in fig. 3.17, the bands corresponding to failing RV and 
LV samples appeared markedly phosphorylated while no signal was found in NF 
samples. 
 
 
 
Fig. 3.17: Representative immunoblot of tyrosine phosphorylation of catalase (CAT) in 
human RV and LV from non failing (NF) and failing (F) hearts with IHD or DCM. The 
bands were detected with a specific antibody for phospho-tyrosine, as described in 
Chapter 2. 
 
3. 3. 6. Correlation between NADPH oxidase and antioxidant enzymes 
activities 
In order to verify the link between oxidative stress and the activation of antioxidant 
enzymes, we investigated possible correlations between the activity of NADPH oxidase 
and the activity of CAT and GPx in the RV and LV. As shown in fig. 3.18, a significant 
and positive correlation was found between the values of NADPH oxidase-dependent 
superoxide production and both CAT (fig. 3.18 A) (RV: r = 0.8142, p < 0.0007; LV: r = 
                                                                                                                                          RESULTS 
 100
0.7784, p < 0.0001) and GPx (fig. 3.18 B) (RV: r = 0.6897, p = 0.0091; LV: r = 0.8744, 
p = 0.0001) activities in LV and RV.  
 
 
 
Fig. 3.18: Correlations between NADPH-dependent superoxide production and GPx 
(A) or CAT (B) enzymatic activity of the same failing and non failing hearts; n = 5 NF 
and n = 8 failing ventricles from hearts with IHD and DCM. MLU, mean arbitrary light 
units. ▲, RV; ■, LV. 
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Of interest, the slope of linear correlation appeared to be steeper in LV than in RV 
for both CAT (LV: m = 1.007; RV: m = 0.354) and GPx (LV: m = 2.416; RV: m = 
1.485), suggesting that antioxidant defences react more intensively to oxidative stress 
damage in LV than in RV. 
 
3. 3. 7. Lipid peroxidation 
Consistently with the differences observed in antioxidant enzymes activities, MDA 
levels measured as an indirect marker of ROS activity, were significantly elevated in 
both ventricles from failing hearts (fig. 3.19). However, diseased RV exhibited a 
particularly marked increase in lipoperoxidative damage compared to NF control (RV 
from failing hearts: 1.80 fold increase Vs RV from non failing hearts; LV from failing 
hearts: 1.51 fold increase Vs LV from non failing hearts). 
 
 
 
Fig. 3.19: MDA content in human RV (open bars) and LV (solid bars) from non failing 
and failing hearts. Data are presented as mean ± S.E.M. and expressed as fold increase 
relative to NF. ** p < 0.01 Vs NF; † p < 0.05 Vs RV failing hearts. n = 5 NF and n = 12 
failing ventricles from hearts with IHD or DCM. 
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3. 4. PART II – 3rd STUDY: NADPH oxidase-dependent redox 
signalling in end-stage human failing hearts secondary to MIC 
 
3. 4. 1. NADPH-dependent superoxide production 
As observed for the precedent two studies, superoxide production was minimal in 
myocardial homogenate from LV failing and non failing hearts both in the absence of 
substrates and in the presence of succinate (data not shown). After the addition of 
NADPH, O2·¯ production raised significantly in all FH compared with control samples. 
However, this phenomenon was more intense in MIC, with a 2-fold increase in O2·¯ 
production compared with DCM and IHD (fig. 3.20 A). Detection of superoxide was 
virtually abolished by tiron. To investigate the sources of superoxide production, 
experiments were repeated in the presence of specific inhibitors of potential ROS-
generating systems. In all failing hearts samples, O2·¯ generation was significantly 
decreased by DPI, confirming the phagocyte-type NADPH oxidase as a major source of 
O2·¯. In addition, MIC hearts showed a significant decrease in O2·¯ production in the 
presence of rotenone and oxypurinol (fig. 3.20 B), whereas the presence of L-NAME 
ester hydrochloride had no effect (data not shown). 
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Fig. 3.20: (A) NADPH-dependent superoxide production in human LV from non failing 
(NF) and failing hearts secondary to IHD, DCM and MIC detected by lucigenin 
chemiluminescence. MLU, mean arbitrary light units. * p < 0.05 and *** p < 0.001 Vs 
NF; ††† p < 0.001 Vs IHD and DCM. n = 8 NF and n = 9, n = 4, n = 3 failing ventricles 
from hearts with IHD, DCM and MIC, respectively. Data are presented as mean ± 
S.E.M. (B) Effect of specific oxidases inhibitors on NADPH-dependent superoxide 
production in LV from human failing hearts secondary to MIC in the absence (NoI) or 
presence of the specific inhibitors DPI, tiron, rotenone or oxypurinol. Data are presented 
as mean ± S.E.M and expressed as percentage Vs NoI sample. *** p < 0.001 and ** p < 
0.01 Vs NoI. 
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3. 4. 2. Antioxidant enzymes defences: glutathione peroxidase 
GPx enzymatic activity did not show any significant change in LV MIC hearts, despite 
a clear trend toward an increase (fig. 3.21). The lack of statistically significant change in 
GPX activity may be due to variability within the control groups. The same variability 
should be also the main cause of both the apparent or the statistically significant 
decrease of GPx activity in LV DCM or IHD, respectively. Such a decrease appears in 
contrast with the results showed in § 3. 3. 3.  
 
 
 
Fig. 3.21: Enzymatic activity of GPx in human LV from non failing (NF) and failing 
hearts secondary to IHD, DCM and MIC detected by a spectrophotometric method. * p 
< 0.05 Vs NF. n = 8 NF and n = 9, n = 4, n = 3 failing ventricles from hearts with IHD, 
DCM and MIC, respectively. Data are presented as mean ± S.E.M and expressed as fold 
increase Vs NF hearts. 
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3. 4. 3. Antioxidant enzymes defences: mitochondrial superoxide dismutase 
Mn-SOD enzymatic activity appeared unchanged in LV failing hearts from MIC, IHD 
and DCM biopsies, relative to LV non failing hearts (fig. 3.22). 
 
 
 
 
Fig. 3.22: Enzymatic activity of Mn-SOD in human LV from non failing (NF) and 
failing hearts secondary to IHD, DCM and MIC detected by a spectrophotometric 
method. n = 8 NF and n = 9, n = 4, n = 3 failing ventricles from hearts with IHD, DCM 
and MIC, respectively. Data are presented as mean ± S.E.M and expressed as fold 
increase Vs NF hearts.  
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CHAPTER 4 
 
DISCUSSION 
 
 
 
 
4. 1. Role of NADPH oxidase-dependent superoxide production in 
H9c2 cells subjected to simulated ischemia/reperfusion  
The most novel finding of this study is that the production of ROS derived from 
NADPH oxidase was enhanced in cardiac myoblasts subjected to a prolonged simulated 
ischemia followed by 1 h reperfusion. The increased ROS intracellular content was 
associated to an enhanced lipid peroxidation, to the activation of specific redox-
sensitive kinases and to cell death. The use of NADPH oxidase activity inhibitor DPI 
during reperfusion largely prevented simulated I/R induced ROS production; the latter 
matched a reduction in MDA content, a significant decrease in p-JNK/JNK ratio and an 
evident protection against cell death.  
The main aim of our study was to describe the role of NADPH oxidase in cardiac 
muscle cells exposed to simulated I/R. In fact, albeit several recent studies have 
examined the influence of myocardial I/R on NADPH oxidase, there are only few and 
conflicting data about the contribution of this oxidase complex to I/R-cell damage and 
its regulation. The present investigation follows our previous demonstration that, in the 
myocardium from end-stage ischemic and non ischemic cardiomyopathies, an increased 
NADPH oxidase activity was significantly correlated with enhanced lipid peroxidation 
and activation of redox sensitive kinases, particularly ERK and p38. The limitation on 
finding a clear evidence for a cause-effect relationship in end-stage hearts53 is the reason 
for using H9c2 cardiomyoblasts line in the present study. This cell line, sharing features 
of adult cardiomyocytes261, is considered a valuable model for mechanicistic studies 
aimed to investigate the pathways implicated in cardiac cell death following oxidative 
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stress262. Previous works in this area include studies of oxidative cell damage caused by 
doxorubicin262, hydrogen peroxide263 and ischemia/reperfusion264. As described in the 
chapter of “Experimental procedures”, H9c2 cells were subjected to an in vitro 
simulated 24 h ischemia followed by 1 h of simulated “reperfusion”. Several reports 
have documented the need for long term hypoxia (24–72 h) for the appearance of 
evident damages in primary cultures of neonatal rat cardiac myocytes264 and this is the 
reason why such a prolonged ischemia was used. Unpublished data from our laboratory 
confirmed a similar behaviour also for H9c2 cardiomyoblasts, indicating 24 h of 
simulated ischemia followed by 1 h of reperfusion as the optimal experimental 
condition to obtain significant alterations in this cell line.  
Potential sources of oxidative stress during I/R include mitochondria, NADPH 
oxidase, and xanthine oxidase. However, a comprehensive understanding of the relative 
contributions of these systems during I/R has not yet emerged. In the present study 
cardiomyoblasts exposed to simulated I/R conditions showed an increased intracellular 
ROS production that, as indicated by DCF fluorescence, was remarkably suppressed by 
the superoxide scavenger Tiron. A similar significant reduction was obtained with 
apocynin, widely considered as a specific NADPH oxidase inhibitor, and DPI, a potent 
flavoprotein inhibitor non specific for NADPH oxidase but commonly used as a NOX 
inhibitor. On the other hand, rotenone, a specific mitochondrial oxidase inhibitor and 
oxypurinol, a xanthine oxidase inhibitor, appeared to fail in reducing ROS production. 
These findings suggest that, under our simulated I/R conditions, superoxide was the 
main ROS produced and NADPH oxidase was its major source, although other 
contribution in ROS generation can not be ruled out. The prominent role of NADPH 
oxidase in superoxide generation was confirmed by lucigenin chemiluminescent 
measurements showing that NADPH, but not other added substrates, increased the 
capacity of cardiomyoblasts exposed to simulated I/R to produce this particular radical 
specie. 
Previous investigations in cell and animal models highlighted that NADPH 
oxidase activation occurs through either increased expression or post-translational 
modifications and translocation of the oxidase subunits66,100,265. Recent studies have 
reported in H9c2 cell line the presence of the NOX2/gp91phox isoform previously 
identified in human cardiomyocytes266. In the present study we have confirmed this 
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observation and we have additionally found that the same cells subjected to simulated 
I/R showed an increased expression of NOX2/gp91phox; this effect, observed through 
Western blotting, was furthermore confirmed by immunocytochemical analysis. The 
increase in NOX2/gp91phox after simulated I/R was not abolished by DPI treatment but 
this is a not surprising finding since DPI is an oxidase activity inhibitor and no data 
report its effects on protein expression. 
A parallel translocation of p47phox from the cytosol to the membrane was also 
observed, as shown by a significant increase of the p47phox membrane/cytosol ratio. 
Serine phosphorylation of p47phox by protein kinase C appears to be the prerequisite for 
p47phox translocation and its stable interaction with membrane-bound cytochrome b558, 
which results in oxidase activation100. It is well known that many stimuli, such as 
angiotensin II or TNF-α, can increase NADPH oxidase activity by PKC 
phosphorylation100. PKCs are also important for stress responses in various tissues and 
PKCε is the primary PKC isoform that is affected by hypoxia or ischemia in heart 
muscle267. Recently, some authors have shown that the addition of chelerythrine, a 
broad spectrum PKC inhibitor, or apocynin, a NADPH oxidase inhibitor, before 
reoxygenation of anoxic endothelial cells, decreased O2¯· production to comparable 
levels, indicating a PKC-dependent NADPH oxidase activation268. It seems reasonable 
that also in our experimental model the activation of PKC induces p47phox 
phosphorylation, its subsequent translocation to the membrane and its interaction with 
membrane-bound cytochrome b558, followed by the increased production of superoxide 
radical. 
Recent studies reported that ischemia resulted in NOX2/gp91phox upregulation in 
H9c2 cells and that DPI had no effect on NOX2/gp91phox expression266. In line with this 
finding, we found that DPI treatment did not decrease NOX2/gp91phox expression in our 
cells exposed to simulated I/R, rather it reduced O2¯· generation and p47phox 
translocation. While it is generally accepted that DPI decreases NADPH oxidase-
derived ROS production, a reduced p47phox translocation did not appear so obvious. To 
our knowledge, whereas it is recognized that the interaction of apocynin with the 
oxidase may form a structure that impedes the binding between p47phox subunit and 
cytochrome b558, no data exists about the mechanism by which DPI might interfere with 
the formation of the oxidase complex. This aspect surely needs further investigation, but 
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the above reported findings suggest that under our experimental conditions both the 
increase in NOX2/gp91phox expression and p47phox translocation to the membrane 
contribute to the observed NADPH oxidase activation. 
The ROS-mediated membrane lipid peroxidation has been proposed as a main 
chemical modification resulting in cell death269. In our experimental conditions, 
cardiomyoblasts subjected to simulated I/R displayed significant increases in lipid 
peroxidation, as shown by their MDA levels, and in cell death. Both these events were 
prevented by DPI treatment, which indicates, in agreement with previous findings270, 
NADPH oxidase-generated ROS as one of the most important contributors to the I/R-
induced lipid peroxidation and the related effects, including cell death. 
In this connection, although the downstream pathways through which NADPH 
oxidase activation could lead to cardiac cell death remain to be fully elucidated, it has 
recently been demonstrated that myocardial I/R activates MAPK subfamilies, including 
the stress responsive JNK and p38, both involved in cell death, and ERK, implicated in 
cell survival signalling. However, p38 does not appear to be activated in all I/R models 
and some authors reported that during ischemia the increase of p38 activity is initially 
rapid but subsequently declines rapidly271. In agreement with these observations, we did 
not find any modification of the p-p38/p38 ratio under our experimental conditions. 
Instead, we observed a significant activation of ERK and, to a higher extent, of JNK, 
whose phosphorylation was positively and significantly correlated with the cell death 
indexes. DPI treatment of I/R cardiac myoblasts did not affect p-ERK/ERK ratio, 
whereas it significantly decreased JNK phosphorylation, suggesting a different 
mechanism of I/R-induced activation for these two MAPKs. The DPI effect on JNK 
activation was similar to that observed with SP600125, a specific inhibitor of JNK. 
Interestingly, these two unrelated inhibitors displayed a similar protective effect also in 
preventing I/R cell death. Taken together, these findings suggest that the NADPH 
oxidase-derived superoxide production plays a relevant role in JNK activation, as 
demonstrated by the positive and significant correlation between the two events. In turn, 
JNK activation appears to be determinant to induce cell death after simulated I/R. 
The simultaneous activation of this kinase and ERK is not surprising and many in 
vivo and in vitro studies reported a concomitant activation of these two kinases after 
hypoxia/ischemia and reoxygenation. Moreover, when stimuli concomitantly activate 
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multiple MAPKs the physiological response to stimulus will depend on the time course 
and strength of the signal. The balance between MAPK activation levels may influence 
cellular fate and turn towards cell death or life. In our experimental model, the 
concomitant activation of ERK and JNK might explain the moderate increase (about 
26%) in cell death observed in post-ischemic reperfused cells. Moreover, the partial 
reduction of ERK phosphorylation following DPI treatment suggests that this process, 
at least in our experimental conditions, was activated by other factors in addition to 
oxidative stress. 
I/R-triggered cardiomyocyte death can occur by either apoptosis or necrosis. 
However, it should be considered that the mode of cell death resulting from I/R injury 
depends, to some extent, on the experimental conditions, and that necrosis and apoptosis 
represent only the extremes of a continuum of various modes of cell death. At any rate, 
we did not assess the relative incidence of these two forms of cell death, since this issue 
was beyond the scope of the study. 
In conclusion, in this study we have pointed out the NADPH oxidase as a critical 
enzyme for the increase in I/R-induced oxidant generation in cardiac cells. At the same 
time, we provided evidence for the mechanism of NADPH oxidase activation. 
Furthermore, the inhibition of the NADPH oxidase by the flavoenzyme inhibitor DPI 
largely prevents I/R induced lipoperoxidative damage and the activation of JNK 
pathway, associated to cell death, without affecting the ERK related survival response. 
We are conscious that this study was performed using both a non-contractile cell line, 
that poorly took account of the load factor, and an in vitro model of simulated 
ischemia/reperfusion, that is devoid of any exogenous neuro-humoral influence. In spite 
of these limitations, the marked improvement of cell survival, as a result of 
NOX2/gp91phox inhibition in our experimental conditions, stress the importance to 
perform further investigation, including in vivo studies to outline cardioprotective 
strategies against I/R injury, a condition of great importance in the clinical setting. 
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4. 2. Role of NADPH oxidase-dependent superoxide production in end-
stage human failing hearts secondary to ischemic and non ischemic 
cardiomyopathies 
 
4. 2. 1. First study 
This study demonstrates for the first time that in human heart failure, increased ROS 
generation by NADPH oxidase is significantly related with enhanced lipid peroxidation 
and activation of redox-sensitive kinases. Our results extend the previous and scant 
findings obtained in the diseased human heart, mostly focused on single aspects of the 
complex oxidative stress pathway66,272, and those inferred from studies in cellular and 
animal models65,100,273. Our data give an insight into the chain of biochemical 
mechanisms arising from increased NADPH oxidase activity, and originally 
demonstrate that these events are present in the right and left ventricle, with a 
significant correlation between the two chambers. 
NADPH oxidase has been addressed as a major source of O2¯· in human vascular 
cells and cardiomyocytes66,188. Studies in cellular and animal models of hypertrophy 
highlighted that NADPH oxidase activation occurs in response to hypertrophic stimuli, 
including angiotensin II, noradrenaline and mechanical overload. In this study, we 
provide evidence of a coordinated increase of NADPH oxidase activity in the right and 
left ventricle of individual failing hearts. We focused our attention on the 
NOX2/gp91phox NADPH oxidase subunit and on p47phox. In agreement with a recent 
study performed in animal model of pacing-induced heart failure274, we did not find an 
increased NOX2/gp91phox protein expression in LV or RV homogenates from terminally 
failing hearts (data not shown). These data appeared in contrast with previous 
observation in human acutely infarcted heart198. This may not be contradictory, since in 
the infarcted heart, a localized increase in NOX2/gp91phox is likely the expression of an 
inflammatory phase of tissue repair198. Conversely, in the present molecular and 
biochemical study, myocardial samples with minimal amounts of fibrosis and devoid of 
inflammatory infiltrate were selected. Another piece of the complex picture of NADPH 
oxidase-mediated signalling comes from recent studies in knockout mice, challenged 
with different hypertrophic stimuli. NOX2/gp91phox contributed to interstitial fibrosis 
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and contractile dysfunction caused by pressure overload, but was not essential to 
NADPH-dependent superoxide generation and for cardiac hypertrophy. In contrast, 
NOX2/gp91phox seems to play a crucial role in the hypertrophic response to angiotensin 
II. Taken together, the present and previous data suggest that increased NOX2/gp91phox 
expression is not a prerequisite for increased NADPH-dependent ROS production. 
On the other hand, we found both overexpression and membrane translocation of 
the regulatory subunit p47phox. Consistently with our findings, an increased expression 
of p47phox mRNA consequent to aortic constriction occurs in NOX2-/- mice, where it 
supports enhanced NADPH oxidase activity191. Interestingly, the relative contribution of 
the two regulatory mechanisms to NADPH oxidase activation appeared different in the 
two ventricles. Despite a lower homogenate p47phox subunit expression, the ratio of 
p47phox membrane bound to its cytosolic protein expression was higher in RV than in 
LV. Likely, this may depend on the fact that even a relatively low number of 
overexpressed p47phox subunits translocated from cytosol to membrane are sufficient to 
produce a sharp increase in p47phox membrane/cytosol ratio and, accordingly, in 
NADPH oxidase activity. Indeed, p47phox translocation well correlated with NADPH 
oxidase activity in both ventricles, thus reinforcing the hypothesis that - in the human 
diseased heart - this mechanism is a requirement for enzyme activation. These results 
agree with previous findings showing that angiotensin II-induced ROS production is 
critically dependent on the p47phox subunit and that pressure overload-induced 
myocardial hypertrophy in gp91phox deficient mice is associated with increased mRNA 
p47phox191. An original feature of the present study consists in trying to establish a 
precise correlation between NADPH oxidase-dependent superoxide generation and 
specific redox-regulated signalling pathways in human heart failure. In fact, the 
increased NADPH oxidase activity was associated with a parallel development of 
oxidative stress, as judged by the levels of MDA, the classical marker of lipid 
peroxidation. The latter mechanism is known to contribute to loss of membrane 
integrity and alteration of cellular functions. Moreover, experimental evidence exists of 
a relationship between MDA levels and the activation of redox-sensitive kinases, in 
particular p38259. In turn, p38 activation elicits a negative inotropic effect on cardiac 
myocytes and is possibly implicated in the progression of heart failure. In agreement 
with these observations, we found a significant positive correlation between relative 
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MDA content and p38 activation in human failing hearts. However, signalling pathways 
linking oxidative stress to pathophysiological response appear to be complex and 
differently regulated. In fact, first of all, we observed that, besides the aforementioned 
p38, ERK but not JNK was correlated to NADPH-dependent ROS production in end-
stage failing hearts. The explanation of this finding is not obvious, since JNK is also 
known to be a stress-activated protein kinase. In experimental models, the activation of 
JNK is an early event in the onset of LV hypertrophy and declines during the 
development of heart failure, despite persistently increased NADPH oxidase activity65. 
On the contrary, activation of p38 and ERK occurs at the transition toward heart 
failure65, and all our diseased samples were obtained from terminally failing hearts. 
Second, we found a higher degree of ERK activation in failing RV than LV. A merely 
speculative hypothesis is that ERK activation in response to oxidative stress depends on 
the increment rather than the absolute value of ROS levels. 
Another novel finding of this study is the demonstration of a coordinated increase 
in NADPH oxidase activity, ROS generation and activation of specific redox-sensitive 
signalling pathways in the two ventricles. These data elicit questions about the 
mechanisms operating in this setting. Myocytes stretching, as a result of increased 
hemodynamic load, appears different in the two ventricles, although pressure overload 
due to secondary pulmonary hypertension occurs in end-stage heart failure. 
Interestingly, we observed a significant correlation between NADPH oxidase activity 
assessed in RV and the pulmonary artery pressure measured in the same patient. This 
finding suggests that mechanical overstretch of the right ventricle causes an increase in 
NADPH oxidase-dependent ROS generation. On the other hand, systemic and local 
alterations of the neurohormonal environment are likely operative in both ventricles, 
and may equally activate NADPH oxidase. 
The findings of our study should be interpreted in the contest of their limitations. 
A mechanistic interpretation of the events downstream to NADPH oxidase activation is 
prevented in human end-stage hearts and therefore our results cannot provide a clear 
evidence for a cause–effect relationship. However, the highly significant correlations 
among ROS production, p47phox translocation and phosphorylation of specific MAP 
kinases are suggestive of a close association among these factors. Another insight 
provided by the present investigation is the correlation between the left and right 
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ventricle from the same patient, a report of scientific and prospectively clinical 
relevance. A rigorous statistical interpretation of such a correlation is difficult, since 
control, IHD or DCM values tend to cluster. This might indicate that, in our conditions, 
the etiology rather than the severity of the disease is crucial for the tested parameters; 
however, all diseased samples came from patients with end-stage heart failure. Studies 
in animal models with different degree of cardiac disease will hopefully allow a deeper 
understanding of the mutual relationship between left and right ventricular remodelling 
and causal mechanisms. Notwithstanding these limitations, as recently pointed out275, 
advancing knowledge about molecular and functional characteristics of the right 
ventricle might lead to progress in the treatment of cardiomyopathies. In conclusion, 
notwithstanding the relative contribution of systemic and hemodynamic factors 
operative in human heart failure, that could differently activate distinct ROS sources 
and related redox signalling, our data strongly suggest that oxidative stress may 
contribute to harmful RV (besides LV) remodelling. Taking into account the role of RV 
function as a predictor of survival in heart failure patients, this observation provides 
new insights into the pathophysiological processes involved in the progression to end-
stage heart failure and supports the therapeutic targeting of ROS-dependent processes.  
 
4. 2. 2. Second study 
The main finding of the present study is that, in human heart failure, activation of 
antioxidant enzymes is related to an increase in oxidative stress. This adaptive response 
mainly occurs through a post-translation modification of antioxidant enzymes 
coordinated in the right and left ventricle, without any changes in their relative protein 
expression. Moreover, human failing LV appears more protected than RV against 
oxidative stress damage.  
The present results extend our previous findings aimed to assess the cascade of 
events triggered by increased NADPH oxidase activation in human failing right and left 
ventricles  (§ 4. 2. 1). Besides confirming a high and significant O2¯· production by a 
NADPH oxidase system in human failing hearts, this study sheds light on the molecular 
mechanisms underlying the increase of this activity. Through collaboration with the 
Department of Preclinical and Clinical Pharmacology at the University of Florence, 
mRNA expression of the two cardiac isoforms of the catalytic subunit of NADPH 
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oxidase, NOX2 and NOX4, were examined. These subunits are known to be differently 
modulated by hypertrophic stimuli . We did not observe any increase in their 
expressions, being mRNA levels for NOX4 unchanged and those for NOX2 
significantly decreased in both RV and LV compared to non failing ventricles. This 
latter finding raises the possibility of a cross-regulation of NADPH oxidase subunits, 
such that loss of NOX2/gp91phox leads to increased expression of other subunits 
involved in NADPH oxidase activation . Indeed, such an hypothesis is in good 
agreement with our previous observation of an overexpression and membrane 
translocation of p47phox in human failing hearts and supports the prominent role of 
p47phox for NADPH oxidase activation . 
A major contribution of our results consists in the characterization of the mutual 
relationship between oxidant and antioxidant activity in RV and LV from human failing 
hearts. Experiments on the level of antioxidant enzymes mRNA were performed at the 
Department of Experimental Medicine at “La Sapienza” University of Rome. 
Previous studies on antioxidant enzymes in human heart failure showed 
inconsistent results. In line with some authors  we did not find changes in mRNA 
expression and protein levels of CAT and GPx in human failing hearts. On the contrary, 
CAT and GPx enzyme activities were markedly increased in failing RV and LV 
compared with NF ventricles. These data suggest that dissociation might occur between 
mRNA/protein expression of these enzymes and their activities. Therefore, the adaptive 
response to increased oxidative stress does not lead to increase transcription of these 
antioxidant enzymes but may reflect a post-translational modification. 
Although the molecular mechanism underlying CAT (or GPx) activation could 
not be thoroughly instigated in this setting, both recent evidence in literature and our 
present results indicate a role of protein (Tyr)-phosphorylation. As a matter of fact, Cao 
and co-worker  reported that in response to in vitro exposure to hydrogen peroxide the 
Abl family of mammalian non-receptor tyrosine kinases, including c-Abl and Arg, were 
activated. This activation was associated with the phosphorylation of CAT and GPx in 
specific tyrosine residues and with subsequent stimulation of their activity. Our 
evidence of an increased CAT (Tyr)-phosphorylation in both ventricles of failing hearts 
strongly suggests that this mechanism is operative also in human failing hearts. So, it is 
reasonable to hypothesize that the activation of c-Abl and Arg kinases and subsequent 
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stimulation of the catalytic activities of CAT and GPx provide a mechanism, albeit 
insufficient, to normalize the level of oxidative stress. To our knowledge, this is the first 
evidence supporting this intriguing hypothesis in human heart.  
Differently from CAT and GPx, Mn-SOD activity was decreased in failing human 
ventricles, despite its gene expression was unchanged or even increased in RV. 
Therefore, similarly to CAT and GPx, the decrease in Mn-SOD activity might be 
attributed to post-translational modification. Indeed, experimental evidence in vivo 
indicates that MnSOD is nitrated and inactivated under pathological conditions, 
including cardiovascular disease . Thus, the possibility that inactivation of Mn-SOD by 
nitration in human heart failure remains a potential explanation that warrants deeper 
studies. 
Notwithstanding the molecular mechanism underlying the modulation of 
antioxidant enzymatic defences, another original feature of the present study is the 
establishment of a correlation between NADPH-dependent ROS production and 
antioxidant enzyme activity in failing right and left ventricles. For both CAT and GPx 
activities, the slope of linear correlation appeared steeper in LV than in RV, suggesting 
a greater protection of the LV against oxidative stress damage. Consistently, failing LV 
exhibited higher CAT activity and lower MDA content compared to those measured in 
the failing RV. This finding underlines the involvement and the contribution of RV on 
the pathophysiological process leading to end-stage heart failure, and, as recently 
pointed out , support for its further investigation. 
The present results suggest a correlation between oxidative stress and activation 
of antioxidant enzymes both in the left and the right ventricle from failing hearts. 
Despite the difficulties related to the clarification of a molecular mechanism 
interpretation in human end-stage hearts, our findings support the hypothesis that this 
activation may be due to post-translation modifications, in particular through 
phoshorylation of Tyr residues. Although qualitatively similar changes occur in both 
chambers, RV seems to be less protected than LV against oxidative stress damage. In 
the paucity of basic knowledge on RV alterations, this finding provides new hints to the 
involvement of the RV in the pathophysiology of heart disease. In this perspective, our 
study is in keeping with the expectation that gathering information on RV 
maladaptation may translate into a better treatment and prevention of heart failure. 
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4. 3. Role of oxidative stress in end-stage human failing hearts 
secondary to mitochondrial cardiomyopathies 
To better clarify the molecular mechanisms linking mtDNA mutations to cardiac 
hypertrophy and failure, we performed a study on failing hearts from 3 patients with 
tRNAIle mutation-related MIC. We evaluated myocardial oxidative stress by assessing 
myocardial superoxide production, and activity of the antioxidant enzymes 
mitochondrial MnSOD and GPx. In collaboration with the Department of Experimental 
Medicine at “La Sapienza” University of Rome gene expression profiles of antioxidant 
enzymes were evaluated. Moreover, key regulators of mitochondrial biogenesis and 
cardiac energy metabolism to failing human hearts due to other causes and to non 
failing hearts were compared.  
Emerging evidence points to energy derangement as a major culprit for 
development of cardiac hypertrophy and progression to heart failure, both in acquired 
and in inherited disease. In recent years, numerous studies using experimental models of 
pressure overload and in human FH have consistently demonstrated a myocardial shift 
from fatty acid oxidation toward glucose oxidation for energy production276. This 
metabolic switch is associated with the down-regulation of genes involved in 
mitochondrial biogenesis and fatty acid metabolism and is mediated by deactivation of 
the transcriptional regulator PPAR-α and its coactivator PGC-1α277,278. The increased 
reliance of hypertrophic myocytes on glycolytic pathways is likely finalized to reduce 
oxygen consumption; however, it may contribute to the progression of cardiac disease, 
possibly creating a relative energy-deficient state. In the study, we revealed that there 
was a specific metabolic gene expression profile in a cardiomyopathy caused by a 
significant derangement of the mitochondrial energy production pathway. As a matter of 
fact, a marked up-regulation of PPAR-α and its coactivator PGC-1α, along with a slight 
increase in the expression of PGC-1β, were observed. Accordingly, the induction of 
genes involved in fatty acid metabolism, glucose transport, and mitochondrial 
biogenesis was detected. This last change is consistent with a dramatic increase in 
mtDNA content per cell, as well as with histologic and ultrastructural features of 
marked mitochondrial proliferation. In contrast, down-regulation of the PPAR- α /PGC-
1 α complex and their targets, as well as reduced expression of glucose transporters, was 
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observed in DCM and IHD from failing hearts, confirming previous observations278. 
Interestingly, the expression level of PGC-1 β showed opposite behaviour in DCM and 
IHD. These data suggest that the 2 homologues are regulated by different mechanisms 
in cardiac myocytes, as reported for brown adipose tissue279. The coordinated induction 
in bioenergetic gene expression observed in MIC is likely to represent a compensatory 
response to energy deficiency. A global defect of oxidative phosphorylation (OXPHOS) 
in MIC hearts, with very low activities of respiratory chain complexes I and IV (both 
containing mtDNA-encoded subunits), was previously observed15. Increase of 
mitochondrial biogenesis (i.e., an increase in mitochondrial mass and induction of 
OXPHOS gene as well as enzymes of intermediary metabolism) is a well known 
phenomenon in mitochondrial disorders. In skeletal muscle, mitochondrial proliferation 
has been shown to partly compensate for the respiratory dysfunction by maintaining 
overall ATP production280; the histopathologic hallmark of this phenomenon is the 
presence of an increased number of mitochondria, mostly in the subsarcolemmal region. 
However, in cardiac muscle, induction of mitochondrial biogenesis has been proposed 
as a maladaptive response. In fact, cardiac-specific induction of PGC-1α in mice results 
in cardiac dysfunction with morphologic features of myocyte mitochondrial 
proliferation and myofibrillar disorganization and loss. Intriguingly, both mitochondrial 
proliferation and cardiomyopathy are reversible upon cessation of transgene expression. 
The present findings parallel the features reported in that experimental model, 
suggesting that mitochondrial proliferation is linked to progressive cardiac dysfunction 
also in the human heart.  
Histological analysis performed at the Department of Experimental Medicine, at 
Rome, showed an altered sarcomere alignment, suggesting that mitochondrial 
proliferation per se may possibly interfere with contractile function; this phenomenon is 
limited to cardiomyocytes: In fact, in skeletal muscle from patients, lack of morphologic 
evidence of mitochondrial proliferation correlates with normal muscle function15. This 
observation opens new perspectives on the complex issue of tissue specificity of 
homoplasmic mitochondrial mutations. 
An interesting result of our present study is the observation of a more pronounced 
increase in myocardial ROS production in MIC compared with DCM and IHD. In our 
experimental conditions, NADPH oxidase was a major source of ROS in all failing 
                                                                                                                                   DISCUSSION 
 119
hearts, as previously reported66. However, the present results implicate both the 
mitochondrial respiratory chain and xanthine oxidase as a source of excessive 
superoxide. Thus, mitochondrial dysfunction may contribute to the increased oxidative 
stress both by mitochondrial-derived O2¯· and by a reduction of ATP/adenosine 
monophosphate ratio, which in turn activates the xanthine oxidase pathways. A 
somewhat paradoxic observation in the present study relates to the observation of high 
levels of ROS in the presence of increased expression of UCP2 and UCP3 in MIC. In 
fact, UCPs are expected to dissipate the proton electrochemical gradient formed during 
mitochondrial respiration and generate heat instead of ATP, thus reducing 
mitochondrial superoxide production. On the other hand, this mechanism may also lead 
to an increase in mitochondrial oxygen consumption, thus amplifying the energy 
dysfunction observed in MIC. We may speculate that the increase in UCP expression in 
MIC is insufficient to decrease ROS production through the mechanism of uncoupling 
respiration, and, therefore, high levels of ROS are maintained. Alternatively, recent 
studies on adipose tissue and skeletal muscle suggest that UCPs are regulated at post-
translational level281. Increased ROS production in MIC was not reflected by a parallel 
induction of antioxidant enzyme activity, despite a marked up-regulation of MnSOD 
and GPx genes. Similar results have been previously reported in human FH210 and in a 
mouse model of MIC16 and support the hypothesis that end-stage heart muscle is unable 
to respond to oxidative stress by adequately increasing antioxidant countermeasures. 
The increase in ROS production observed in MIC is of great interest because growing 
evidence has implicated ROS signalling in cardiac maladaptive remodelling. However, 
additional work is required to fully address this issue. A metabolic gene expression 
profile similar to MIC has been reported in the cardiomyopathy that develops in the 
context of diabetes. In that condition, increase of circulating free fatty acids may lead to 
activation of PPAR-α/PGC-1α complex, which in turn causes induction of 
mitochondrial biogenesis and fatty acid oxidation.  
The present results suggest that mitochondrial biogenesis is a maladaptive 
response in MIC and, possibly, in other metabolic cardiomyopathies. Besides energy 
deficiency, mechanical interference with sarcomere alignment and contraction, 
increased oxidative stress, and uncoupled respiration are possible detrimental factors to 
myocyte function.  
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